[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 1232
1. Scott RH, Homfray T, Huxter NL, Mitton SG, Nash R, Potter MN, Lancaster D, Rahman N: Familial T-cell non-Hodgkin lymphoma caused by biallelic MSH2 mutations. J Med Genet; 2007 Jul;44(7):e83
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Familial T-cell non-Hodgkin lymphoma caused by biallelic MSH2 mutations.
  • Familial non-Hodgkin lymphoma (NHL) is rare and in most cases, no underlying cause is identifiable.
  • Q76X) in three siblings who each developed T-cell NHL in early childhood.
  • Constitutional biallelic MSH2 mutations have previously been reported in five individuals, all of whom developed malignancy in childhood.


2. Smedby KE, Hjalgrim H, Chang ET, Rostgaard K, Glimelius B, Adami HO, Melbye M: Childhood social environment and risk of non-Hodgkin lymphoma in adults. Cancer Res; 2007 Nov 15;67(22):11074-82
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Childhood social environment and risk of non-Hodgkin lymphoma in adults.
  • Better hygiene and sanitation and decreasing family size parallel the increasing incidence of non-Hodgkin lymphoma (NHL) in many populations around the world.
  • We investigated how family structure and childhood social environment were related to the risk of NHL and NHL subtypes in a large Scandinavian population-based case control study with 6,242 participants aged 18 to 74 years.
  • Our findings add to the evidence that large sibship size, late birth order, and childhood crowding are associated with an elevated risk of NHL.
  • Effect mechanisms may be related to early age at onset and high frequency of specific infections or total microbial exposure in childhood.
  • [MeSH-major] Environment. Lymphoma, Non-Hodgkin / diagnosis. Lymphoma, Non-Hodgkin / etiology


3. Kadan-Lottick NS, Zeltzer LK, Liu Q, Yasui Y, Ellenberg L, Gioia G, Robison LL, Krull KR: Neurocognitive functioning in adult survivors of childhood non-central nervous system cancers. J Natl Cancer Inst; 2010 Jun 16;102(12):881-93
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neurocognitive functioning in adult survivors of childhood non-central nervous system cancers.
  • BACKGROUND We sought to measure self-reported neurocognitive functioning among survivors of non-central nervous system (CNS) childhood cancers, overall and compared with a sibling cohort, and to identify factors associated with worse functioning.
  • METHODS In a retrospective cohort study, 5937 adult survivors of non-CNS cancers and 382 siblings completed a validated neuropsychological instrument with subscales in task efficiency, emotional regulation, organization, and memory.
  • Non-CNS cancer survivors and siblings were compared with multivariable linear regression and log-binomial regression.
  • RESULTS Non-CNS cancer survivors had similar or slightly worse (<0.5 standard deviation) mean test scores for all four subscales than siblings.
  • Impaired task efficiency was most often identified in patients with acute lymphoblastic leukemia who received cranial radiation therapy (18.1% with impairment), myeloid leukemia who received cranial radiation therapy (21.2%), and non-Hodgkin lymphoma (13.9%).
  • CONCLUSION A statistically and clinically significantly higher percentage of self-reported neurocognitive impairment was found among survivors of non-CNS cancers than among siblings.

  • MedlinePlus Health Information. consumer health - Cancer in Children.
  • MedlinePlus Health Information. consumer health - Cancer--Living with Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 2001 Apr 19;344(16):1207-13 [11309635.001]
  • [Cites] Psychosomatics. 2001 May-Jun;42(3):241-6 [11351113.001]
  • [Cites] Neurology. 2001 Jun 12;56(11):1539-45 [11402112.001]
  • [Cites] Child Neuropsychol. 2000 Sep;6(3):235-8 [11419452.001]
  • [Cites] Med Pediatr Oncol. 2002 Apr;38(4):229-39 [11920786.001]
  • [Cites] J Pediatr Hematol Oncol. 2002 Feb;24(2):106-14 [11990695.001]
  • [Cites] Med Pediatr Oncol. 2002 May;38(5):320-8 [11979456.001]
  • [Cites] Pediatrics. 2002 Jul;110(1 Pt 1):42-52 [12093945.001]
  • [Cites] Eur J Cancer. 2003 Feb;39(3):359-65 [12565989.001]
  • [Cites] Cancer. 2003 Feb 15;97(4):1115-26 [12569614.001]
  • [Cites] Lancet Oncol. 2004 Jul;5(7):399-408 [15231246.001]
  • [Cites] Lancet. 1981 Nov 7;2(8254):1015-8 [6118478.001]
  • [Cites] Pediatrics. 1985 Apr;75(4):745-53 [3838584.001]
  • [Cites] Biometrics. 1986 Mar;42(1):121-30 [3719049.001]
  • [Cites] J Clin Oncol. 1988 Feb;6(2):315-20 [3422262.001]
  • [Cites] J Child Psychol Psychiatry. 1988 Nov;29(6):839-52 [3069852.001]
  • [Cites] Am J Pediatr Hematol Oncol. 1989 Spring;11(1):74-86 [2496615.001]
  • [Cites] Dev Med Child Neurol. 1990 Mar;32(3):238-48 [2311827.001]
  • [Cites] J Clin Oncol. 1991 Jan;9(1):145-51 [1985164.001]
  • [Cites] J Clin Oncol. 1991 Aug;9(8):1348-56 [2072138.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1992;22(1):13-6 [1727109.001]
  • [Cites] J Pediatr. 1992 Dec;121(6):885-9 [1447650.001]
  • [Cites] Lancet. 1994 Jul 23;344(8917):224-7 [7913156.001]
  • [Cites] J Clin Oncol. 1998 May;16(5):1712-22 [9586883.001]
  • [Cites] J Pediatr Psychol. 1998 Oct;23(5):333-40 [9782681.001]
  • [Cites] J Pediatr Psychol. 2005 Jan-Feb;30(1):65-78 [15610986.001]
  • [Cites] Pediatr Blood Cancer. 2005 Sep;45(3):281-90 [15806539.001]
  • [Cites] J Pediatr Hematol Oncol. 2000 May-Jun;22(3):206-13 [10864051.001]
  • [Cites] J Clin Oncol. 2006 Aug 20;24(24):3858-64 [16921038.001]
  • [Cites] J Natl Cancer Inst. 2006 Dec 6;98(23):1742-5 [17148777.001]
  • [Cites] J Clin Oncol. 2007 Nov 1;25(31):4914-21 [17971588.001]
  • [Cites] Pediatrics. 2007 Nov;120(5):e1229-36 [17974716.001]
  • [Cites] Neuropsychol Rev. 2008 Jun;18(2):121-31 [18415683.001]
  • [Cites] J Clin Oncol. 2008 Jun 20;26(18):3025-30 [18565888.001]
  • [Cites] Cancer. 2008 Oct 15;113(8):2188-97 [18792068.001]
  • [Cites] Pediatr Blood Cancer. 2009 Feb;52(2):159-64 [18680151.001]
  • [Cites] J Int Neuropsychol Soc. 2009 Jan;15(1):31-41 [19128526.001]
  • [Cites] J Clin Oncol. 2009 May 10;27(14):2308-18 [19364948.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2009 Oct;18(10):2626-35 [19815636.001]
  • [Cites] Neuropsychology. 2009 Nov;23(6):705-17 [19899829.001]
  • [Cites] Eur J Pharmacol. 2010 Jan 10;626(1):83-6 [19835870.001]
  • [CommentIn] J Natl Cancer Inst. 2011 Apr 6;103(7):607; author reply 607-9 [21350219.001]
  • (PMID = 20458059.001).
  • [ISSN] 1460-2105
  • [Journal-full-title] Journal of the National Cancer Institute
  • [ISO-abbreviation] J. Natl. Cancer Inst.
  • [Language] ENG
  • [Grant] United States / NCRR NIH HHS / RR / KL2 RR024138; United States / NCI NIH HHS / CA / U24-CA55727
  • [Publication-type] Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2886093
  •  go-up   go-down


Advertisement
4. Wehrli LA, Braun J, Buetti LN, Hagleitner N, Hengartner H, Kühne T, Lüer S, Ozsahin H, Popovic MB, Niggli FK, Betts DR, Bourquin JP: Non-classical karyotypic features in relapsed childhood B-cell precursor acute lymphoblastic leukemia. Cancer Genet Cytogenet; 2009 Feb;189(1):29-36
Genetic Alliance. consumer health - Acute Non Lymphoblastic Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Non-classical karyotypic features in relapsed childhood B-cell precursor acute lymphoblastic leukemia.
  • Karyotype analysis of acute lymphoblastic leukemia (ALL) at diagnosis has provided valuable prognostic markers for treatment stratification.
  • Non-classical cytogenetic aberrations in these 29 patients were mostly found on chromosomes 1, 2, 7, 9, 13, 14, and 17.
  • From 29 patients with non-classical cytogenetic aberrations, only 8 (28%) had been stratified to a high risk-arm on the first treatment protocol, suggesting that this subgroup might benefit from the identification of new prognostic markers in future studies.
  • [MeSH-major] Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / genetics
  • [MeSH-minor] Acute Disease. Adolescent. Child. Child, Preschool. Chromosome Aberrations. Female. Humans. Infant. Karyotyping. Male. Recurrence. Translocation, Genetic. Treatment Outcome


5. Zuna J, Cavé H, Eckert C, Szczepanski T, Meyer C, Mejstrikova E, Fronkova E, Muzikova K, Clappier E, Mendelova D, Boutard P, Schrauder A, Sterba J, Marschalek R, van Dongen JJ, Hrusak O, Stary J, Trka J: Childhood secondary ALL after ALL treatment. Leukemia; 2007 Jul;21(7):1431-5
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Childhood secondary ALL after ALL treatment.
  • Data on secondary acute lymphoblastic leukaemia (sALL) following ALL treatment are very rare.
  • We focused on the recurrences of childhood ALL to discover the real frequency of the sALL after ALL treatment.
  • [MeSH-major] Molecular Diagnostic Techniques / methods. Neoplasms, Second Primary / diagnosis. Precursor Cell Lymphoblastic Leukemia-Lymphoma / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17460701.001).
  • [ISSN] 0887-6924
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


6. Ye QD, Gu LJ, Tang JY, Xue HL, Chen J, Pan C, Chen J, Dong L, Zhou M: [ALL-XH-99 protocol in the treatment of childhood T-cell acute lymphoblastic leukemia]. Zhonghua Xue Ye Xue Za Zhi; 2009 Jan;30(1):26-8
Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia, Childhood.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [ALL-XH-99 protocol in the treatment of childhood T-cell acute lymphoblastic leukemia].
  • OBJECTIVE: To analyze the incidence, clinical characteristics and prognosis of childhood T-cell acute lymphoblastic leukemia (T-ALL).
  • RESULTS: Of 305 childhood ALL patients, 43 were T-ALL.
  • CONCLUSION: There were statistic differences between T-cell and B-cell childhood ALLs in age, initial WBC count, early response to therapy, and eight-year EFS and RFS.
  • Childhood T-ALL was associated with a worse prognosis than other sub-types of childhood ALL.
  • [MeSH-major] Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Disease-Free Survival. Female. Humans. Immunophenotyping. Infant. Karyotyping. Male. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / genetics. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / immunology. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / pathology. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / therapy. Prognosis

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19563031.001).
  • [ISSN] 0253-2727
  • [Journal-full-title] Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
  • [ISO-abbreviation] Zhonghua Xue Ye Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  •  go-up   go-down


7. Burjanivova T, Madzo J, Muzikova K, Meyer C, Schneider B, Votava F, Marschalek R, Stary J, Trka J, Zuna J: Prenatal origin of childhood AML occurs less frequently than in childhood ALL. BMC Cancer; 2006;6:100
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prenatal origin of childhood AML occurs less frequently than in childhood ALL.
  • BACKGROUND: While there is enough convincing evidence in childhood acute lymphoblastic leukemia (ALL), the data on the pre-natal origin in childhood acute myeloid leukemia (AML) are less comprehensive.
  • Our study aimed to screen Guthrie cards (neonatal blood spots) of non-infant childhood AML and ALL patients for the presence of their respective leukemic markers.
  • CONCLUSION: In the largest cohort examined so far we used identical approach for the backtracking of non-infant childhood ALL and AML.
  • [MeSH-major] Biomarkers, Tumor / blood. DNA, Neoplasm / blood. Fetal Blood / chemistry. Gene Rearrangement, B-Lymphocyte. Gene Rearrangement, T-Lymphocyte. Leukemia, Myeloid / embryology. Oncogene Proteins, Fusion / blood. Precursor Cell Lymphoblastic Leukemia-Lymphoma / embryology
  • [MeSH-minor] Bone Marrow Cells / chemistry. Child. Child, Preschool. Clone Cells / chemistry. Cohort Studies. Core Binding Factor Alpha 2 Subunit / blood. Core Binding Factor Alpha 2 Subunit / genetics. Female. Gene Duplication. Humans. Infant. Infant, Newborn. Male. Myeloid-Lymphoid Leukemia Protein / blood. Myeloid-Lymphoid Leukemia Protein / genetics. Neonatal Screening. Neoplasm Proteins / blood. Neoplasm Proteins / genetics. Polymerase Chain Reaction. Tandem Repeat Sequences. fms-Like Tyrosine Kinase 3 / blood. fms-Like Tyrosine Kinase 3 / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Haematol. 2003 Jul;122(1):24-9 [12823342.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Jan 11;102(2):449-54 [15626757.001]
  • [Cites] Blood. 2003 Oct 1;102(7):2321-33 [12791663.001]
  • [Cites] Lancet. 1999 Oct 30;354(9189):1499-503 [10551495.001]
  • [Cites] Blood. 1999 Dec 1;94(11):3707-16 [10572083.001]
  • [Cites] Blood. 2000 Jul 1;96(1):264-8 [10891460.001]
  • [Cites] Blood. 2001 Jan 1;97(1):89-94 [11133746.001]
  • [Cites] Blood. 2001 Jul 15;98(2):478-82 [11435320.001]
  • [Cites] Blood. 2001 Oct 1;98(7):2272-4 [11568017.001]
  • [Cites] Blood. 2002 Apr 15;99(8):2992-6 [11929791.001]
  • [Cites] Blood. 2002 May 15;99(10):3801-5 [11986239.001]
  • [Cites] Blood. 2002 Oct 1;100(7):2387-92 [12239146.001]
  • [Cites] Blood. 2002 Oct 1;100(7):2393-8 [12239147.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Nov 12;99(23):15101-6 [12415113.001]
  • [Cites] Br J Cancer. 2002 Oct 21;87(9):994-9 [12434291.001]
  • [Cites] Genes Chromosomes Cancer. 2003 May;37(1):36-43 [12661004.001]
  • [Cites] Blood. 2003 Jun 1;101(11):4640-1 [12756163.001]
  • [Cites] Genes Chromosomes Cancer. 2003 Aug;37(4):406-11 [12800152.001]
  • [Cites] Leukemia. 2003 Nov;17(11):2202-6 [12931229.001]
  • [Cites] Leuk Lymphoma. 2003 Dec;44(12):2099-102 [14959854.001]
  • [Cites] Genes Chromosomes Cancer. 2004 Apr;39(4):335-40 [14978794.001]
  • [Cites] Nucleic Acids Res. 1988 Feb 11;16(3):1215 [3344216.001]
  • [Cites] Nucleic Acids Res. 1995 Sep 25;23(18):3788-9 [7479012.001]
  • [Cites] Blood. 1997 Jan 1;89(1):281-5 [8978302.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Dec 9;94(25):13950-4 [9391133.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 May 26;95(11):6413-8 [9600980.001]
  • [Cites] J Pediatr Hematol Oncol. 1998 May-Jun;20(3):264-7 [9628441.001]
  • [Cites] Leukemia. 1999 Jan;13(1):110-8 [10049045.001]
  • [Cites] Blood. 1999 May 1;93(9):3074-80 [10216104.001]
  • [Cites] Blood. 1999 Jun 15;93(12):4079-85 [10361104.001]
  • [Cites] Blood. 1999 Aug 1;94(3):1057-62 [10419898.001]
  • [Cites] Leukemia. 2003 Aug;17(8):1667-9 [12886258.001]
  • (PMID = 16630339.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / AML1-ETO fusion protein, human; 0 / Biomarkers, Tumor; 0 / CBFbeta-MYH11 fusion protein; 0 / Core Binding Factor Alpha 2 Subunit; 0 / DNA, Neoplasm; 0 / MLL-AF10 fusion protein, human; 0 / MLL-AF6 fusion protein, human; 0 / Neoplasm Proteins; 0 / Oncogene Proteins, Fusion; 0 / TEL-AML1 fusion protein; 0 / promyelocytic leukemia-retinoic acid receptor alpha fusion oncoprotein; 149025-06-9 / Myeloid-Lymphoid Leukemia Protein; EC 2.7.10.1 / FLT3 protein, human; EC 2.7.10.1 / fms-Like Tyrosine Kinase 3
  • [Other-IDs] NLM/ PMC1463004
  •  go-up   go-down


8. Cox CV, Diamanti P, Evely RS, Kearns PR, Blair A: Expression of CD133 on leukemia-initiating cells in childhood ALL. Blood; 2009 Apr 2;113(14):3287-96
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of CD133 on leukemia-initiating cells in childhood ALL.
  • Optimization of therapy for childhood acute lymphoblastic leukemia (ALL) requires a greater understanding of the cells that proliferate to maintain this malignancy because a significant number of cases relapse, resulting from failure to eradicate the disease.
  • We investigated expression of CD133, CD19, and CD38 in pediatric B-ALL.
  • Furthermore, these CD133(+)/CD19(-) ALL cells were more resistant to treatment with dexamethasone and vincristine, key components in childhood ALL therapy, than the bulk leukemia population.
  • These data suggest that leukemia-initiating cells in childhood B-ALL have a primitive CD133(+)/CD19(-) and CD38(-) phenotype.
  • [MeSH-major] Antigens, CD / metabolism. Glycoproteins / metabolism. Neoplastic Stem Cells / metabolism. Peptides / metabolism. Precursor Cell Lymphoblastic Leukemia-Lymphoma / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Blood. 2009 Apr 30;113(18):4476-7; author reply 4477 [19407001.001]
  • (PMID = 19147788.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / AC133 antigen; 0 / Antigens, CD; 0 / Antigens, CD19; 0 / Glycoproteins; 0 / Immunoglobulin Heavy Chains; 0 / Membrane Glycoproteins; 0 / Peptides; EC 3.2.2.5 / Antigens, CD38; EC 3.2.2.5 / CD38 protein, human
  •  go-up   go-down


9. Park MJ, Taki T, Oda M, Watanabe T, Yumura-Yagi K, Kobayashi R, Suzuki N, Hara J, Horibe K, Hayashi Y: FBXW7 and NOTCH1 mutations in childhood T cell acute lymphoblastic leukaemia and T cell non-Hodgkin lymphoma. Br J Haematol; 2009 Apr;145(2):198-206
Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] FBXW7 and NOTCH1 mutations in childhood T cell acute lymphoblastic leukaemia and T cell non-Hodgkin lymphoma.
  • Mutation analysis of FBXW7 and NOTCH1 genes was performed in 55 T cell acute lymphoblastic leukaemia (T-ALL) and 14 T cell non-Hodgkin lymphoma (T-NHL) patients who were treated on the Japan Association of Childhood Leukaemia Study (JACLS) protocols ALL-97 and NHL-98.
  • [MeSH-major] Cell Cycle Proteins / genetics. F-Box Proteins / genetics. Gene Expression Regulation, Leukemic. Lymphoma, T-Cell / genetics. Mutation. Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / genetics. Receptor, Notch1 / genetics. Ubiquitin-Protein Ligases / genetics


10. Hundsdoerfer P, Dietrich I, Schmelz K, Eckert C, Henze G: XIAP expression is post-transcriptionally upregulated in childhood ALL and is associated with glucocorticoid response in T-cell ALL. Pediatr Blood Cancer; 2010 Aug;55(2):260-6
Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] XIAP expression is post-transcriptionally upregulated in childhood ALL and is associated with glucocorticoid response in T-cell ALL.
  • BACKGROUND: Resistance to glucocorticoid induced apoptosis is one of the major risk factors for relapse and poor outcome in childhood acute lymphoblastic leukemia (ALL).
  • PROCEDURE: XIAP protein and mRNA expression were determined in leukemic blasts of 51 childhood ALL patients and normal bone marrow mononuclear cells.
  • RESULTS: XIAP protein but not mRNA expression was found to be highly increased in childhood ALL compared to control bone marrow mononuclear cells (MNC) (median: 3.5 vs. 0.14 ng/10(5) MNC, P < 0.0001) indicating a post-transcriptional regulation of XIAP expression.
  • CONCLUSION: In childhood ALL compared to control bone marrow, the expression of the apoptosis inhibitor XIAP is highly increased by post-transcriptional regulation.
  • [MeSH-major] Gene Expression Regulation, Leukemic. Glucocorticoids / pharmacology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. X-Linked Inhibitor of Apoptosis Protein / genetics
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / pharmacology. Bone Marrow Cells / pathology. Bone Marrow Examination. Child. Drug Resistance. Female. Humans. Leukemia-Lymphoma, Adult T-Cell / drug therapy. Male. Monocytes / pathology. Pharmacogenetics. Prognosis. RNA, Messenger / analysis. Treatment Outcome. Up-Regulation

  • MedlinePlus Health Information. consumer health - Steroids.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2010 Wiley-Liss, Inc.
  • (PMID = 20582956.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Glucocorticoids; 0 / RNA, Messenger; 0 / X-Linked Inhibitor of Apoptosis Protein
  •  go-up   go-down


11. Reiter A: Diagnosis and treatment of childhood non-hodgkin lymphoma. Hematology Am Soc Hematol Educ Program; 2007;:285-96
Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnosis and treatment of childhood non-hodgkin lymphoma.
  • Major advances have been made in the treatment of childhood non-Hodgkin lymphoma (NHL).
  • Currently established therapy groups are lymphoblastic lymphoma (LBL) of precursor B- or T-cell type, mature B-cell neoplasms (B-NHL), and anaplastic large cell lymphoma (ALCL).
  • Therapy protocols designed to treat children with acute lymphoblastic leukemia (ALL) have proven highly efficacious for treating children with LBL and are associated with event-free survival (EFS) rates up to 80%.
  • A variety of new treatment options, some already established for treating adult NHL, await evaluation in childhood NHL.


12. Goldman S, Coiffier B, Reiter A, Younes A, Cairo MS, International TLS Expert Panel: A medical decision tree for the prophylaxis (P) and treatment (T) of tumor lysis syndrome (TLS): An international TLS consensus panel. J Clin Oncol; 2009 May 20;27(15_suppl):e17575

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: We convened an international panel (N = 17) of experts in pediatric and adult hematological malignancies and solid tumors (ST) to develop a medical decision tree for the P and T of TLS based on the risk classification (low, medium, high) and management recommendations of Coiffier et al (J Clin Oncol.
  • MRD consisted of ALL ≤100K/mm<sup>3</sup>, AML 25-100K/mm<sup>3</sup>, BL/LL stage I/II and low LDH, childhood ALCL, DLBCL/PTCL/MCL/ATL non-bulky but elevated LDH, CLL treated with targeted therapy, and LRD with renal impairment/involvement.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963935.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


13. Fronkova E, Mejstrikova E, Avigad S, Chik KW, Castillo L, Manor S, Reznickova L, Valova T, Zdrahalova K, Hrusak O, Jabali Y, Schrappe M, Conter V, Izraeli S, Li CK, Stark B, Stary J, Trka J: Minimal residual disease (MRD) analysis in the non-MRD-based ALL IC-BFM 2002 protocol for childhood ALL: is it possible to avoid MRD testing? Leukemia; 2008 May;22(5):989-97
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Minimal residual disease (MRD) analysis in the non-MRD-based ALL IC-BFM 2002 protocol for childhood ALL: is it possible to avoid MRD testing?
  • MRD negativity at day 33 was associated with an age of 1-5 years, WBC<20,000 microl(-1), non-T immunophenotype, good prednisone response and non-M3 morphology at day 15.
  • [MeSH-major] Neoplasm, Residual / diagnosis. Precursor Cell Lymphoblastic Leukemia-Lymphoma / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18305563.001).
  • [ISSN] 1476-5551
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


14. Huang L, Lequin M, Pieters R, van den Heuvel-Eibrink MM: The clinical value of follow-up examinations in childhood T-cell acute lymphoblastic leukemia and T-cell non-Hodgkin's lymphoma. Pediatr Blood Cancer; 2007 Apr;48(4):468-72
Genetic Alliance. consumer health - Lymphoblastic lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The clinical value of follow-up examinations in childhood T-cell acute lymphoblastic leukemia and T-cell non-Hodgkin's lymphoma.
  • BACKGROUND: The aim of this study was to evaluate the value of follow-up investigations of T-cell acute lymphoblastic leukemia (T-ALL) and T-cell non-Hodgkin's lymphoma (T-NHL), including cerebrospinal fluid (CSF) examination, bone marrow (BM) aspiration, peripheral blood (PB) count, serum lactate dehydrogenase (LDH) and chest X-rays in patients with an initial mediastinal enlargement.
  • PROCEDURE: We reviewed clinical records of all T-ALL patients from 1987 to 2002 and all T-NHL patients from 1977 to 2002, seen at a single institution.
  • All T-ALL and T-NHL patients with a mediastinal relapse were symptomatic.
  • [MeSH-major] Leukemia-Lymphoma, Adult T-Cell / diagnosis. Lymphoma, T-Cell / diagnosis


15. Schrauder A, Reiter A, Gadner H, Niethammer D, Klingebiel T, Kremens B, Peters C, Ebell W, Zimmermann M, Niggli F, Ludwig WD, Riehm H, Welte K, Schrappe M: Superiority of allogeneic hematopoietic stem-cell transplantation compared with chemotherapy alone in high-risk childhood T-cell acute lymphoblastic leukemia: results from ALL-BFM 90 and 95. J Clin Oncol; 2006 Dec 20;24(36):5742-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Superiority of allogeneic hematopoietic stem-cell transplantation compared with chemotherapy alone in high-risk childhood T-cell acute lymphoblastic leukemia: results from ALL-BFM 90 and 95.
  • PURPOSE: The role of hematopoietic stem-cell transplantation (SCT) in first complete remission (CR1) for children with very high-risk (VHR) acute lymphoblastic leukemia (ALL) is still under critical discussion.
  • CONCLUSION: SCT in CR1 is superior to treatment with chemotherapy alone for childhood HR-T-ALL.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hematopoietic Stem Cell Transplantation. Leukemia-Lymphoma, Adult T-Cell / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy


16. Bilić E, Femenić R, Konja J, Simat M, Dubravcić K, Batinić D, Ries S, Rajić L: CD20 positive childhood B-non Hodgkin lymphoma (B-NHL): morphology, immunophenotype and a novel treatment approach: a single center experience. Coll Antropol; 2010 Mar;34(1):171-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CD20 positive childhood B-non Hodgkin lymphoma (B-NHL): morphology, immunophenotype and a novel treatment approach: a single center experience.
  • Lymphomas represent the third most common group of cancers in childhood and adolescence, mature B non Hodgkin's lymphoma (B-NHL) accounting for up to 60% of newly diagnosed patients.
  • The effect of rituximab in pediatric population is still not well enough investigated.
  • The number of our patients is too small and the follow-up of a larger group of patients will help in defining the role of rituximab in the treatment of childhood B-NHL.


17. Schmiegelow K, Forestier E, Hellebostad M, Heyman M, Kristinsson J, Söderhäll S, Taskinen M, Nordic Society of Paediatric Haematology and Oncology: Long-term results of NOPHO ALL-92 and ALL-2000 studies of childhood acute lymphoblastic leukemia. Leukemia; 2010 Feb;24(2):345-54
Pharmacogenomics Knowledge Base. meta-databases - Pharmacogenomic Annotation 1183701935 for PMID:20010622 [PharmGKB] .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term results of NOPHO ALL-92 and ALL-2000 studies of childhood acute lymphoblastic leukemia.
  • Analysis of 2668 children with acute lymphoblastic leukemia (ALL) treated in two successive Nordic clinical trials (Nordic Society of Paediatric Haematology and Oncology (NOPHO) ALL-92 and ALL-2000) showed that 75% of all patients are cured by first-line therapy, and 83% are long-term survivors.
  • Improved risk stratification and chemotherapy have eliminated the previous independent prognostic significance of gender, CNS leukemia and translocation t(1;19)(q23;p13), whereas the post-induction level of minimal residual disease (MRD) has emerged as a new risk grouping feature.
  • Infant leukemia, high leukocyte count, T-lineage immunophenotype, translocation t(4;11)(q21;q23) and hypodiploidy persist to be associated with lower cure rates.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy


18. Oguz A, Tayfun T, Citak EC, Karadeniz C, Tatlicioglu T, Boyunaga O, Bora H: Long-term pulmonary function in survivors of childhood Hodgkin disease and non-Hodgkin lymphoma. Pediatr Blood Cancer; 2007 Oct 15;49(5):699-703
MedlinePlus Health Information. consumer health - Hodgkin Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term pulmonary function in survivors of childhood Hodgkin disease and non-Hodgkin lymphoma.
  • BACKGROUND: The aim of our study was to evaluate the long-term effects of chemotherapy and/or radiotherapy on lung function in 75 childhood Hodgkin disease (HD) and non-Hodgkin lymphoma (NHL) survivors several years after treatment.
  • RESULTS: No patients reported acute or chronic respiratory symptoms or diseases.
  • CONCLUSION: Chemotherapy or chemo-radiotherapy-induced pulmonary sequalae in childhood may remain asymptomatic for many years.
  • [MeSH-major] Hodgkin Disease / complications. Lung / physiopathology. Lymphoma, Non-Hodgkin / complications


19. Mann G, Attarbaschi A, Steiner M, Simonitsch I, Strobl H, Urban C, Meister B, Haas O, Dworzak M, Gadner H, Austrian Berlin-Frankfurt-Münster (BFM) Group: Early and reliable diagnosis of non-Hodgkin lymphoma in childhood and adolescence: contribution of cytomorphology and flow cytometric immunophenotyping. Pediatr Hematol Oncol; 2006 Apr-May;23(3):167-76
Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Early and reliable diagnosis of non-Hodgkin lymphoma in childhood and adolescence: contribution of cytomorphology and flow cytometric immunophenotyping.
  • Non-Hodgkin lymphoma (NHL) represents one of the most rapidly growing malignancies in childhood and adolescence.
  • The authors identified 23 patients with Burkitt lymphoma by the combination of FAB L3 morphology and a mature B-cell phenotype and 22 patients with lymphoblastic lymphoma by FAB L1/L2 morphology and a T-/B-cell precursor phenotype.
  • Burkitt lymphoma, lymphoblastic lymphoma, and, in a few cases, some large cell lymphomas could be classified reliably by cytomorphology and immunophenotyping of freshly obtained tumor cell material, enabling an early start of specific lymphoma treatment.
  • [MeSH-major] Cytological Techniques. Flow Cytometry. Immunophenotyping. Lymphoma, Non-Hodgkin / diagnosis
  • [MeSH-minor] Abdominal Neoplasms / classification. Abdominal Neoplasms / diagnosis. Abdominal Neoplasms / pathology. Adolescent. Antigens, CD / analysis. Austria / epidemiology. Biopsy, Fine-Needle. Burkitt Lymphoma / diagnosis. Burkitt Lymphoma / pathology. Cell Nucleus / ultrastructure. Cell Size. Child. Child, Preschool. Cytoplasm / ultrastructure. Early Diagnosis. Feasibility Studies. Female. Humans. In Situ Hybridization, Fluorescence. Infant. Lymphocyte Subsets / pathology. Lymphoma, Large B-Cell, Diffuse / diagnosis. Lymphoma, Large B-Cell, Diffuse / pathology. Male. Mediastinal Neoplasms / classification. Mediastinal Neoplasms / diagnosis. Mediastinal Neoplasms / pathology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / diagnosis. Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology. Prospective Studies. Staining and Labeling


20. Eden T: Aetiology of childhood leukaemia. Cancer Treat Rev; 2010 Jun;36(4):286-97
Hazardous Substances Data Bank. FOLIC ACID .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Aetiology of childhood leukaemia.
  • The acute leukaemias account for about 30% of all malignancy seen in childhood across the Western world.
  • Many environmental factors have been proposed as causative for leukaemia but only ionising irradiation and certain chemicals, e.g. benzene and cytotoxics (alkylators and topoisomerase II inhibitors) have been confirmed and then principally for acute myeloid leukaemia.
  • It appears increasingly likely that delayed, dysregulated responses to 'common' infectious agents play a major part in the conversion of pre-leukaemic clones into overt precursor B cell ALL, the most common form of childhood leukaemia.
  • High penetrance germ-line mutations are involved in only about 5% of childhood leukaemias (more in AML than ALL).
  • Other environmental factors for which some evidence exists include non-ionising electromagnetic radiation and electric fields, although their mode of action in leukaemogenesis remains unclear.
  • There is no single cause for childhood leukaemia and for most individuals a combination of factors appears to be necessary; all involving gene-environment interactions.
  • [MeSH-major] Leukemia / etiology

  • MedlinePlus Health Information. consumer health - Leukemia.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2010. Published by Elsevier Ltd.
  • (PMID = 20223594.001).
  • [ISSN] 1532-1967
  • [Journal-full-title] Cancer treatment reviews
  • [ISO-abbreviation] Cancer Treat. Rev.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 935E97BOY8 / Folic Acid
  • [Number-of-references] 141
  •  go-up   go-down


21. Kolenova A, Hikkel I, Ilencikova D, Hikkelova M, Sejnova D, Kaiserova E, Cizmar A, Puskacova J, Bubanska E, Oravkinova I, Gencik M: Minimal residual disease detection using real-time quantitative PCR analysis of immunoglobulin and T-cell receptor gene rearrangements in the non-MRD-based ALL IC-BFM 2002 protocol for childhood ALL: Slovak experience. Neoplasma; 2010;57(6):552-61

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Minimal residual disease detection using real-time quantitative PCR analysis of immunoglobulin and T-cell receptor gene rearrangements in the non-MRD-based ALL IC-BFM 2002 protocol for childhood ALL: Slovak experience.
  • Acute lymphoblastic leukemia is the most common form of cancer in children.
  • An intense effort has been made to develop methods to determine the degree of minimal residual leukemia cells present in patients considered to be in morphological remission.
  • A total of 40 patients with BCP-ALL ( B cell precursor ALL) and 4 patients with T ALL were analyzed for Ig/TCR rearrangement.
  • [MeSH-major] Gene Rearrangement. Gene Rearrangement, T-Lymphocyte. Genes, Immunoglobulin. Polymerase Chain Reaction / methods. Precursor Cell Lymphoblastic Leukemia-Lymphoma / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20845994.001).
  • [ISSN] 0028-2685
  • [Journal-full-title] Neoplasma
  • [ISO-abbreviation] Neoplasma
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Slovakia
  •  go-up   go-down


22. Laaksonen MM, Mikkilä V, Räsänen L, Rontu R, Lehtimäki TJ, Viikari JS, Raitakari OT, Cardiovascular Risk in Young Finns Study Group: Genetic lactase non-persistence, consumption of milk products and intakes of milk nutrients in Finns from childhood to young adulthood. Br J Nutr; 2009 Jul;102(1):8-17
Hazardous Substances Data Bank. CALCIUM, ELEMENTAL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Genetic lactase non-persistence, consumption of milk products and intakes of milk nutrients in Finns from childhood to young adulthood.
  • We examined whether the consumption of milk and milk products and the intakes of milk nutrients differ between the lactase genotypes from childhood to young adulthood.
  • Subjects with the lactase non-persistence (C/C- 13910) genotype consumed less milk since childhood, but the consumption of other milk products did not differ between the genotypes.
  • Inadequate Ca intake was most common in females with the C/C- 13910 genotype as early as in childhood (15-63 %), but in males only in adulthood (24 %).

  • MedlinePlus Health Information. consumer health - Lactose Intolerance.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Lactose .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19138442.001).
  • [ISSN] 1475-2662
  • [Journal-full-title] The British journal of nutrition
  • [ISO-abbreviation] Br. J. Nutr.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] EC 3.2.1.108 / Lactase; J2B2A4N98G / Lactose; SY7Q814VUP / Calcium
  •  go-up   go-down


23. Lightfoot T: Aetiology of childhood leukemia. Bioelectromagnetics; 2005;Suppl 7:S5-S11
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Aetiology of childhood leukemia.
  • Leukemia is the most common cancer to affect children, accounting for approximately a third of all childhood cancers.
  • The major morphological subtypes of leukemia, acute lymphoblastic leukemia (ALL), and acute myeloblastic leukemia (AML), are characterized by chromosomal translocations involving over 200 genes including mixed lineage leukemia (MLL), TEL, and AML1.
  • Chromosomal translocations involving the MLL gene at 11q23 are a common feature of infant acute leukemia, found in up to 80% of all cases, and there is strong evidence that rearrangements involving the MLL gene or the TEL-AML1 gene fusion can originate in utero.
  • As with most other cancers, the mechanism by which leukemia arises is likely to involve gene-environment interactions.
  • Exposures acting before birth and early in life has long been thought to be important determinants of leukemia, and the list of suspected chemical, physical, and biological agents continues to increase.
  • Unfortunately, the evidence regarding the majority of suggested exposures is limited and often contradictory, and there are areas, which clearly warrant further investigation in order to further our understanding of the aetiology of childhood leukemia.
  • [MeSH-major] Electromagnetic Fields / adverse effects. Environmental Exposure / adverse effects. Leukemia, Radiation-Induced / etiology. Leukemia, Radiation-Induced / physiopathology. Prenatal Exposure Delayed Effects / etiology. Prenatal Exposure Delayed Effects / physiopathology

  • MedlinePlus Health Information. consumer health - Electromagnetic Fields.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2005 Wiley-Liss, Inc
  • (PMID = 16059922.001).
  • [ISSN] 0197-8462
  • [Journal-full-title] Bioelectromagnetics
  • [ISO-abbreviation] Bioelectromagnetics
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Number-of-references] 54
  •  go-up   go-down


24. Bungaro S, Dell'Orto MC, Zangrando A, Basso D, Gorletta T, Lo Nigro L, Leszl A, Young BD, Basso G, Bicciato S, Biondi A, te Kronnie G, Cazzaniga G: Integration of genomic and gene expression data of childhood ALL without known aberrations identifies subgroups with specific genetic hallmarks. Genes Chromosomes Cancer; 2009 Jan;48(1):22-38
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Integration of genomic and gene expression data of childhood ALL without known aberrations identifies subgroups with specific genetic hallmarks.
  • Pediatric acute lymphoblastic leukemia (ALL) comprises genetically distinct subtypes.
  • To identify genomic aberrancies in childhood ALL patients nonclassifiable by conventional methods, we performed a single nucleotide polymorphisms (SNP) array-based genomic analysis of leukemic cells from 29 cases.
  • [MeSH-major] Polymorphism, Single Nucleotide. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18803328.001).
  • [ISSN] 1098-2264
  • [Journal-full-title] Genes, chromosomes & cancer
  • [ISO-abbreviation] Genes Chromosomes Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / B-Cell-Specific Activator Protein; 0 / Calcium-Binding Proteins; 0 / ETS translocation variant 6 protein; 0 / Genetic Markers; 0 / Intercellular Signaling Peptides and Proteins; 0 / Membrane Proteins; 0 / PAX5 protein, human; 0 / Proto-Oncogene Proteins c-ets; 0 / Repressor Proteins; 0 / Smad1 Protein; 134324-36-0 / Serrate proteins
  •  go-up   go-down


25. Eleftheriou D, Gerschman T, Sebire N, Woo P, Pilkington CA, Brogan PA: Biologic therapy in refractory chronic non-bacterial osteomyelitis of childhood. Rheumatology (Oxford); 2010 Aug;49(8):1505-12
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Biologic therapy in refractory chronic non-bacterial osteomyelitis of childhood.
  • Disease activity was assessed at predetermined time points (T = 0, T = 6 weeks and T = 12 months after the start of biologic therapy, and at latest follow-up) using a combination of clinical examination and radiological findings: a 10 cm pain and physician visual analogue scale; the Childhood Health Assessment Questionnaire as an assessment of disability; and changes in markers of systemic inflammation.

  • Genetic Alliance. consumer health - Osteomyelitis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20430869.001).
  • [ISSN] 1462-0332
  • [Journal-full-title] Rheumatology (Oxford, England)
  • [ISO-abbreviation] Rheumatology (Oxford)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antirheumatic Agents; 0 / Interleukin 1 Receptor Antagonist Protein; 0 / Tumor Necrosis Factor-alpha
  •  go-up   go-down


26. Estes DA, Lovato DM, Khawaja HM, Winter SS, Larson RS: Genetic alterations determine chemotherapy resistance in childhood T-ALL: modelling in stage-specific cell lines and correlation with diagnostic patient samples. Br J Haematol; 2007 Oct;139(1):20-30
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Genetic alterations determine chemotherapy resistance in childhood T-ALL: modelling in stage-specific cell lines and correlation with diagnostic patient samples.
  • Acquired drug resistance eventually leads to treatment failure in T-cell acute lymphoblastic leukaemia (T-ALL).
  • [MeSH-major] Cell Line, Tumor. Drug Resistance, Neoplasm / genetics. Gene Expression Regulation, Leukemic. Genes, MDR. Leukemia-Lymphoma, Adult T-Cell / genetics

  • Hazardous Substances Data Bank. DAUNORUBICIN .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17854304.001).
  • [ISSN] 0007-1048
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / 1 R01 CA114589; United States / NCI NIH HHS / CA / U10 CA98543-03-14305
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / P-Glycoprotein; 0 / RNA, Small Interfering; 5J49Q6B70F / Vincristine; 9PHQ9Y1OLM / Prednisolone; EC 3.5.1.1 / Asparaginase; EC 6.3.1.1 / Aspartate-Ammonia Ligase; EC 6.3.4.5 / Argininosuccinate Synthase; ZS7284E0ZP / Daunorubicin
  •  go-up   go-down


27. Kikuchi A, Mori T, Fujimoto J, Kumagai M, Sunami S, Okimoto Y, Tsuchida M: Outcome of childhood B-cell non-Hodgkin lymphoma and B-cell acute lymphoblastic leukemia treated with the Tokyo Children's Cancer Study Group NHL B9604 protocol. Leuk Lymphoma; 2008 Apr;49(4):757-62
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcome of childhood B-cell non-Hodgkin lymphoma and B-cell acute lymphoblastic leukemia treated with the Tokyo Children's Cancer Study Group NHL B9604 protocol.
  • From June 1996 to January 2001, 91 patients with B-cell non-Hodgkin lymphoma or B-cell acute lymphoblastic leukemia up to 18 years of age were enrolled in Tokyo Children's Cancer Study Group (TCCSG) NHL B9604 protocol study.


28. Dulucq S, St-Onge G, Gagné V, Ansari M, Sinnett D, Labuda D, Moghrabi A, Krajinovic M: DNA variants in the dihydrofolate reductase gene and outcome in childhood ALL. Blood; 2008 Apr 1;111(7):3692-700
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] DNA variants in the dihydrofolate reductase gene and outcome in childhood ALL.
  • Dihydrofolate reductase (DHFR) is the major target of methotrexate (MTX), a key component in childhood acute lymphoblastic leukemia (ALL) treatment.
  • [MeSH-major] Polymorphism, Single Nucleotide. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. Promoter Regions, Genetic / genetics. Tetrahydrofolate Dehydrogenase / genetics

  • Pharmacogenomics Knowledge Base. meta-databases - Pharmacogenomic Annotation 827859583 for PMID:18096764 [PharmGKB] .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • Hazardous Substances Data Bank. FOLIC ACID .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18096764.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Cyclin D; 0 / Cyclins; 0 / DNA, Neoplasm; 0 / RNA, Messenger; 0 / RNA, Neoplasm; 935E97BOY8 / Folic Acid; EC 1.5.1.3 / Tetrahydrofolate Dehydrogenase; EC 2.1.1.45 / Thymidylate Synthase; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


29. Spence W, Mulholland C, Lynch G, McHugh S, Dempster M, Shannon C: Rates of childhood trauma in a sample of patients with schizophrenia as compared with a sample of patients with non-psychotic psychiatric diagnoses. J Trauma Dissociation; 2006;7(3):7-22
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rates of childhood trauma in a sample of patients with schizophrenia as compared with a sample of patients with non-psychotic psychiatric diagnoses.
  • Despite strong evidence of high rates of childhood and adult trauma in schizophrenia, the area remains under-researched.
  • Our objectives in the study were first, to examine the rates of exposure to childhood, adult and lifetime (child plus adult) trauma in a population with schizophrenia and a population with non-psychotic psychiatric diagnoses and second, to examine the effect of trauma on the symptoms of schizophrenia.
  • Two groups, those with schizophrenia (n = 40), and those with a non-psychotic diagnosis (n = 30), were recruited.
  • Childhood exposure to trauma was significantly more common in the schizophrenia group (t = 5.196, df = 68, p < 0.001, Eta squared = 0.28), with the strongest relationship being childhood physical assault.
  • Evidence that childhood exposure to trauma is more common in a population with schizophrenia is consistent with other studies and raises the possibility that such trauma is of etiological importance.
  • Further research is required to replicate those findings, to elucidate possible pathways by which the experience of trauma may contribute to the development of schizophrenia, and to explore the relationship between a history of childhood trauma and the experience of depressive symptoms in schizophrenia.

  • Genetic Alliance. consumer health - Schizophrenia.
  • MedlinePlus Health Information. consumer health - Schizophrenia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16873227.001).
  • [ISSN] 1529-9732
  • [Journal-full-title] Journal of trauma & dissociation : the official journal of the International Society for the Study of Dissociation (ISSD)
  • [ISO-abbreviation] J Trauma Dissociation
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


30. Gaipa G, Basso G, Maglia O, Leoni V, Faini A, Cazzaniga G, Bugarin C, Veltroni M, Michelotto B, Ratei R, Coliva T, Valsecchi MG, Biondi A, Dworzak MN, I-BFM-ALL-FCM-MRD Study Group: Drug-induced immunophenotypic modulation in childhood ALL: implications for minimal residual disease detection. Leukemia; 2005 Jan;19(1):49-56
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Drug-induced immunophenotypic modulation in childhood ALL: implications for minimal residual disease detection.
  • However, we previously noticed modulation of surface antigen expression in acute lymphoblastic leukemia (ALL) during the early treatment.
  • [MeSH-major] Neoplasm, Residual. Precursor Cell Lymphoblastic Leukemia-Lymphoma / immunology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Leukemia. 2005 Oct;19(10):1858 [16107890.001]
  • [CommentIn] Leukemia. 2005 Oct;19(10):1845-7 [16107891.001]
  • (PMID = 15538405.001).
  • [ISSN] 0887-6924
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD
  •  go-up   go-down


31. Salzburg J, Burkhardt B, Zimmermann M, Wachowski O, Woessmann W, Oschlies I, Klapper W, Wacker HH, Ludwig WD, Niggli F, Mann G, Gadner H, Riehm H, Schrappe M, Reiter A: Prevalence, clinical pattern, and outcome of CNS involvement in childhood and adolescent non-Hodgkin's lymphoma differ by non-Hodgkin's lymphoma subtype: a Berlin-Frankfurt-Munster Group Report. J Clin Oncol; 2007 Sep 1;25(25):3915-22
MedlinePlus Health Information. consumer health - Head and Neck Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prevalence, clinical pattern, and outcome of CNS involvement in childhood and adolescent non-Hodgkin's lymphoma differ by non-Hodgkin's lymphoma subtype: a Berlin-Frankfurt-Munster Group Report.
  • PURPOSE: We analyzed the prevalence, clinical pattern, and prognostic impact of CNS involvement in a large cohort of children and adolescents diagnosed with non-Hodgkin's lymphoma (NHL), with special attention to differences according to NHL subtype.
  • The percentage of CNS-positive patients was 8.8% for Burkitt's lymphoma/Burkitt's leukemia (BL/B-ALL), 5.4% for precursor B-lymphoblastic lymphoma (pB-LBL), 3.3% for anaplastic large-cell lymphoma, 3.2% for T-cell-LBL, 2.6% for diffuse large B-cell lymphoma, and 0% for primary mediastinal large B-cell NHL (P < .001).
  • CONCLUSION: Six percent of childhood/adolescent NHL patients were CNS positive.
  • [MeSH-major] Brain Neoplasms / epidemiology. Head and Neck Neoplasms / epidemiology. Lymphoma, Non-Hodgkin / classification. Lymphoma, Non-Hodgkin / epidemiology

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17761975.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


32. Mansur MB, Emerenciano M, Splendore A, Brewer L, Hassan R, Pombo-de-Oliveira MS, Brazilian Collaborative Study Group of Infant Acute Leukemia: T-cell lymphoblastic leukemia in early childhood presents NOTCH1 mutations and MLL rearrangements. Leuk Res; 2010 Apr;34(4):483-6
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] T-cell lymphoblastic leukemia in early childhood presents NOTCH1 mutations and MLL rearrangements.
  • T-cell acute lymphoblastic leukemia (T-ALL) may affect children in very early age.
  • We used standard methods to explore NOTCH1 mutations and other specific molecular markers in 15 early childhood T-ALL cases.
  • Despite being found in a lower frequency than that described for overall pediatric T-ALL, NOTCH1 alterations were the most frequent ones.
  • [MeSH-major] Mutation. Myeloid-Lymphoid Leukemia Protein / genetics. Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / genetics. Receptor, Notch1 / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2009 Elsevier Ltd. All rights reserved.
  • (PMID = 19631984.001).
  • [ISSN] 1873-5835
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / MLL protein, human; 0 / NOTCH1 protein, human; 0 / Receptor, Notch1; 149025-06-9 / Myeloid-Lymphoid Leukemia Protein; EC 2.1.1.43 / Histone-Lysine N-Methyltransferase
  •  go-up   go-down


33. Hotfilder M, Röttgers S, Rosemann A, Schrauder A, Schrappe M, Pieters R, Jürgens H, Harbott J, Vormoor J: Leukemic stem cells in childhood high-risk ALL/t(9;22) and t(4;11) are present in primitive lymphoid-restricted CD34+CD19- cells. Cancer Res; 2005 Feb 15;65(4):1442-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Leukemic stem cells in childhood high-risk ALL/t(9;22) and t(4;11) are present in primitive lymphoid-restricted CD34+CD19- cells.
  • Open questions in the pathogenesis of childhood acute lymphoblastic leukemia (ALL) are which hematopoietic cell is target of the malignant transformation and whether primitive stem cells contribute to the leukemic clone.
  • Fluorescence in situ hybridization analysis, however, shows that none of these myeloid colonies (0 of 41 RT-PCR-positive colonies) originated from a progenitor cell that carries the leukemia-specific translocation.
  • In conclusion, we show that childhood high-risk ALL/t(9;22) and t(4;11) originate in a primitive CD34(+)CD19(-) progenitor/stem cell without a myeloerythroid developmental potential.
  • [MeSH-major] Antigens, CD19 / biosynthesis. Antigens, CD34 / biosynthesis. Neoplastic Stem Cells / pathology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology. Translocation, Genetic / genetics
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Chromosomes, Human, Pair 11 / genetics. Chromosomes, Human, Pair 22 / genetics. Chromosomes, Human, Pair 4 / genetics. Chromosomes, Human, Pair 9 / genetics. Flow Cytometry. Genes, abl / genetics. Humans. In Situ Hybridization, Fluorescence. Myeloid-Lymphoid Leukemia Protein. Oncogene Proteins, Fusion / genetics. Reverse Transcriptase Polymerase Chain Reaction

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15735032.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD19; 0 / Antigens, CD34; 0 / MLL-AF4 fusion protein, human; 0 / Oncogene Proteins, Fusion; 149025-06-9 / Myeloid-Lymphoid Leukemia Protein
  •  go-up   go-down


34. Möricke A, Zimmermann M, Reiter A, Henze G, Schrauder A, Gadner H, Ludwig WD, Ritter J, Harbott J, Mann G, Klingebiel T, Zintl F, Niemeyer C, Kremens B, Niggli F, Niethammer D, Welte K, Stanulla M, Odenwald E, Riehm H, Schrappe M: Long-term results of five consecutive trials in childhood acute lymphoblastic leukemia performed by the ALL-BFM study group from 1981 to 2000. Leukemia; 2010 Feb;24(2):265-84
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term results of five consecutive trials in childhood acute lymphoblastic leukemia performed by the ALL-BFM study group from 1981 to 2000.
  • Between 1981 and 2000, 6609 children (<18 years of age) were treated in five consecutive trials of the Berlin-Frankfurt-Münster (BFM) study group for childhood acute lymphoblastic leukemia (ALL).
  • In parallel to relapse reduction, major efforts focused on reducing acute and late toxicity through advanced risk adaptation of treatment.
  • (1) preventive cranial radiotherapy could be safely reduced to 12 Gy in T-ALL and high-risk (HR) ALL patients, and eliminated in non- HR non-T-ALL patients, if it was replaced by high-dose and intrathecal (IT) MTX;.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cranial Irradiation. Neoplasm Recurrence, Local / therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy. Stem Cell Transplantation


35. Hemmingsson T, Lundberg I: How far are socioeconomic differences in coronary heart disease hospitalization, all-cause mortality and cardiovascular mortality among adult Swedish males attributable to negative childhood circumstances and behaviour in adolescence? Int J Epidemiol; 2005 Apr;34(2):260-7
Genetic Alliance. consumer health - Heart Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] How far are socioeconomic differences in coronary heart disease hospitalization, all-cause mortality and cardiovascular mortality among adult Swedish males attributable to negative childhood circumstances and behaviour in adolescence?
  • Adverse social circumstances in childhood have been related to an increased risk of CHD and mortality in adulthood.
  • METHODS: Data on circumstances in childhood and adolescence, e.g. crowded housing and low social position of the father, measured at age 9-11, was collected among 49,323 men, born in 1949-51, and conscripted for compulsory military training in 1969/70.
  • The relative risk of CHD, all-cause mortality, and cardiovascular mortality among unskilled workers compared with that among high-level non-manual employees was 1.82 (95% CI: 1.36, 2.44), 2.24 (95% CI: 1.72, 2.93), and 2.38 (95% CI: 1.47, 3.86) respectively.
  • The early life risk indicators, such as crowded housing and low childhood social position (measured at age 9-11), short stature (measured at age 18-20), and low education (reported at age 18-20), were more common among those who in 1990 (i.e. at age 39-41) were manual workers than among those who were in non-manual occupations.
  • In multivariate analyses, considering the indicators of childhood social disadvantage and adjusting for lifestyle factors established at age 18-20, (smoking, alcohol consumption, overweight) the increased relative risk of CHD hospitalization and cardiovascular mortality in the four categories of employed workers was reduced by 72-100%.
  • CONCLUSION: Predictors of CHD measured in childhood and adolescence may explain a substantial part of the social gradient in CHD, cardiovascular mortality, and all-cause mortality among the 40-50 year old males studied.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15333622.001).
  • [ISSN] 0300-5771
  • [Journal-full-title] International journal of epidemiology
  • [ISO-abbreviation] Int J Epidemiol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


36. Kotch JB, Lewis T, Hussey JM, English D, Thompson R, Litrownik AJ, Runyan DK, Bangdiwala SI, Margolis B, Dubowitz H: Importance of early neglect for childhood aggression. Pediatrics; 2008 Apr;121(4):725-31
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Importance of early neglect for childhood aggression.
  • OBJECTIVE: The goal was to examine the association between early childhood neglect (birth to age 2 years) and later childhood aggression at ages 4, 6, and 8 years, compared with aggression's associations with early childhood abuse and later abuse and neglect.
  • CONCLUSION: This longitudinal study suggests that child neglect in the first 2 years of life may be a more-important precursor of childhood aggression than later neglect or physical abuse at any age.

  • MedlinePlus Health Information. consumer health - Child Abuse.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18381537.001).
  • [ISSN] 1098-4275
  • [Journal-full-title] Pediatrics
  • [ISO-abbreviation] Pediatrics
  • [Language] eng
  • [Grant] United States / NICHD NIH HHS / HD / R01 HD039689
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  •  go-up   go-down


37. Hutchison RE, Laver JH, Chang M, Muzzafar T, Desai S, Murphy S, Schwenn M, Shuster J, Link MP, Children's Oncology Group: Non-anaplastic peripheral t-cell lymphoma in childhood and adolescence: a Children's Oncology Group study. Pediatr Blood Cancer; 2008 Jul;51(1):29-33
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Non-anaplastic peripheral t-cell lymphoma in childhood and adolescence: a Children's Oncology Group study.
  • While a high proportion of adults with PTCL have poor risk disease, pediatric PTCL is not well characterized.
  • This study examines the outcome of localized and advanced PTCL in pediatric patients treated in standardized fashion.
  • PROCEDURE: We identified 20 pediatric patients diagnosed with PTCL whose tumor cells did not express CD30 and/or ALK, as determined by immunohistochemistry, between 1992 and 2000 on one of two treatment protocols for localized NHL (POG 9219) or advanced stage large cell lymphoma (POG 9315).

  • Genetic Alliance. consumer health - Peripheral T-cell lymphoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 Wiley-Liss, Inc.
  • (PMID = 18300314.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / U10 CA098413; United States / NCI NIH HHS / CA / CA 98543; United States / NCI NIH HHS / CA / U10 CA098543; United States / NCI NIH HHS / CA / U10 CA180899; United States / NCI NIH HHS / CA / U10 CA180886
  • [Publication-type] Journal Article; Multicenter Study; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Other-IDs] NLM/ NIHMS688709; NLM/ PMC4447625
  •  go-up   go-down


38. Flohr T, Schrauder A, Cazzaniga G, Panzer-Grümayer R, van der Velden V, Fischer S, Stanulla M, Basso G, Niggli FK, Schäfer BW, Sutton R, Koehler R, Zimmermann M, Valsecchi MG, Gadner H, Masera G, Schrappe M, van Dongen JJ, Biondi A, Bartram CR, International BFM Study Group (I-BFM-SG): Minimal residual disease-directed risk stratification using real-time quantitative PCR analysis of immunoglobulin and T-cell receptor gene rearrangements in the international multicenter trial AIEOP-BFM ALL 2000 for childhood acute lymphoblastic leukemia. Leukemia; 2008 Apr;22(4):771-82
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Minimal residual disease-directed risk stratification using real-time quantitative PCR analysis of immunoglobulin and T-cell receptor gene rearrangements in the international multicenter trial AIEOP-BFM ALL 2000 for childhood acute lymphoblastic leukemia.
  • Detection of minimal residual disease (MRD) is the most sensitive method to evaluate treatment response and one of the strongest predictors of outcome in childhood acute lymphoblastic leukemia (ALL).
  • [MeSH-major] Gene Rearrangement. Neoplasm, Residual. Precursor Cell Lymphoblastic Leukemia-Lymphoma / diagnosis. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy


39. Stachel D, Albert M, Meilbeck R, Kreutzer B, Haas RJ, Schmid I: Bone marrow Th2 cytokine expression as predictor for relapse in childhood acute lymphoblastic leukemia (ALL). Eur J Med Res; 2006 Mar 27;11(3):102-13
Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia, Childhood.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bone marrow Th2 cytokine expression as predictor for relapse in childhood acute lymphoblastic leukemia (ALL).
  • Samples from 49 consecutive pediatric patients with B cell precursor acute lymphocytic leukemia (BCP ALL) were analyzed by semiquantitative RT-PCR.
  • We identified interleukin (IL)-10 expression as a significant adverse prognostic indicator in childhood BCP-ALL.
  • These findings emphasize the role of the immune system for the outcome of childhood ALL.
  • [MeSH-major] Bone Marrow Cells / immunology. Burkitt Lymphoma / genetics. Burkitt Lymphoma / immunology. Cytokines / genetics. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / genetics. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / immunology. Th2 Cells / immunology

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16751110.001).
  • [ISSN] 0949-2321
  • [Journal-full-title] European journal of medical research
  • [ISO-abbreviation] Eur. J. Med. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antigens, CD86; 0 / CD86 protein, human; 0 / Cytokines; 0 / Interleukin-1; 0 / RNA, Messenger; 0 / RNA, Neoplasm; 130068-27-8 / Interleukin-10; 207137-56-2 / Interleukin-4
  •  go-up   go-down


40. Panagiotakaki E, Gobbi G, Neville B, Ebinger F, Campistol J, Nevsímalová S, Laan L, Casaer P, Spiel G, Giannotta M, Fons C, Ninan M, Sange G, Schyns T, Vavassori R, Poncelin D, ENRAH Consortium, Arzimanoglou A: Evidence of a non-progressive course of alternating hemiplegia of childhood: study of a large cohort of children and adults. Brain; 2010 Dec;133(Pt 12):3598-610
Genetic Alliance. consumer health - Hemiplegia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evidence of a non-progressive course of alternating hemiplegia of childhood: study of a large cohort of children and adults.
  • Alternating hemiplegia of childhood is a neurological disorder characterized by episodes of hemiplegia, various non-epileptic paroxysmal events and global neurological impairment.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20974617.001).
  • [ISSN] 1460-2156
  • [Journal-full-title] Brain : a journal of neurology
  • [ISO-abbreviation] Brain
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Investigator] Arzimanoglou A; Campistol J; Casaer P; Ebinger F; Fons C; Giannotta M; Gobbi G; Kemlink D; Laan L; Neville B; Nevsímalová S; Ninan M; Oechsler C; Panagiotakaki E; Spiel G; Bassi MT; Casari G; Crawley F; Martinelli BF; Nicole S; Poncelin D; Sange G; Schyns T; van den Maagdenberg A; Vavassori R; Zucca C
  •  go-up   go-down


41. Veerman AJ, Kamps WA, van den Berg H, van den Berg E, Bökkerink JP, Bruin MC, van den Heuvel-Eibrink MM, Korbijn CM, Korthof ET, van der Pal K, Stijnen T, van Weel Sipman MH, van Weerden JF, van Wering ER, van der Does-van den Berg A, Dutch Childhood Oncology Group: Dexamethasone-based therapy for childhood acute lymphoblastic leukaemia: results of the prospective Dutch Childhood Oncology Group (DCOG) protocol ALL-9 (1997-2004). Lancet Oncol; 2009 Oct;10(10):957-66
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dexamethasone-based therapy for childhood acute lymphoblastic leukaemia: results of the prospective Dutch Childhood Oncology Group (DCOG) protocol ALL-9 (1997-2004).
  • BACKGROUND: A population-based cohort of children aged 1-18 years with acute lymphoblastic leukaemia (ALL) was treated with a dexamethasone-based protocol (Dutch Childhood Oncology Group [DCOG] ALL-9).
  • We aimed to confirm the results of the most effective DCOG ALL protocol for non-high-risk (NHR) patients to date (ALL-6), compare results with ALL-7 and ALL-8, and study prognostic factors in a non-randomised setting.
  • [MeSH-major] Antineoplastic Agents, Hormonal / administration & dosage. Antineoplastic Combined Chemotherapy Protocols. Brain Neoplasms / drug therapy. Dexamethasone / administration & dosage. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Lancet Oncol. 2009 Oct;10(10):932-3 [19747877.001]
  • (PMID = 19747876.001).
  • [ISSN] 1474-5488
  • [Journal-full-title] The Lancet. Oncology
  • [ISO-abbreviation] Lancet Oncol.
  • [Language] eng
  • [Publication-type] Controlled Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 7S5I7G3JQL / Dexamethasone
  •  go-up   go-down


42. Cloppenborg T, Stanulla M, Zimmermann M, Schrappe M, Welte K, Klein C: Immunosurveillance of childhood ALL: polymorphic interferon-gamma alleles are associated with age at diagnosis and clinical risk groups. Leukemia; 2005 Jan;19(1):44-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunosurveillance of childhood ALL: polymorphic interferon-gamma alleles are associated with age at diagnosis and clinical risk groups.
  • To determine whether a CA-repeat associated with differential NFkappaB-binding and IFN-gamma-expression levels may influence the incidence, manifestation and early clinical treatment response of childhood acute lymphoblastic leukemia, we performed PCR-based genotyping of 393 patients with ALL and 207 healthy controls.
  • [MeSH-major] Interferon-gamma / genetics. Polymorphism, Genetic. Precursor Cell Lymphoblastic Leukemia-Lymphoma / immunology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15496974.001).
  • [ISSN] 0887-6924
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 82115-62-6 / Interferon-gamma
  •  go-up   go-down


43. Turrell G, Lynch JW, Leite C, Raghunathan T, Kaplan GA: Socioeconomic disadvantage in childhood and across the life course and all-cause mortality and physical function in adulthood: evidence from the Alameda County Study. J Epidemiol Community Health; 2007 Aug;61(8):723-30
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Socioeconomic disadvantage in childhood and across the life course and all-cause mortality and physical function in adulthood: evidence from the Alameda County Study.
  • OBJECTIVE: To measure the childhood and life course socioeconomic exposures of people born between 1871 and 1949, and then to estimate the probability of death between 1965 and 1994, the probability of functional limitation in 1994, and the combined probability of dying or experiencing functional limitation during this period.
  • Socioeconomic position (SEP) in childhood was based on respondent's reports of their father's occupation, and life course disadvantage was measured by cross-classifying childhood SEP and the respondent's education and household income in 1965.
  • RESULTS: Those from a low SEP in childhood, and those exposed to a greater number of episodes of disadvantage over the life course before 1965, were subsequently more likely to die, to report functional limitation and to experience the greatest health-related burden.
  • CONCLUSIONS: All-cause mortality, functional limitation and overall health-related burden in middle and late adulthood are shaped by socioeconomic conditions experienced during childhood and cumulative disadvantage over the life course.
  • The contributions made to adult health by childhood SEP and accumulated disadvantage suggest that each constitutes a distinct socioeconomic influence that may require different policy responses and intervention options.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Epidemiol. 2000 Oct;29(5):871-7 [11034971.001]
  • [Cites] Aust N Z J Public Health. 2006 Aug;30(4):353-61 [16956166.001]
  • [Cites] Science. 2001 Feb 23;291(5508):1491-2 [11234076.001]
  • [Cites] J Clin Epidemiol. 2001 May;54(5):501-10 [11337214.001]
  • [Cites] Int J Epidemiol. 2002 Apr;31(2):285-93 [11980781.001]
  • [Cites] BMJ. 2002 Nov 9;325(7372):1076-80 [12424168.001]
  • [Cites] Soc Sci Med. 2003 Nov;57(9):1643-52 [12948573.001]
  • [Cites] J Epidemiol Community Health. 2003 Oct;57(10):778-83 [14573579.001]
  • [Cites] Am J Epidemiol. 2004 Mar 1;159(5):481-90 [14977644.001]
  • [Cites] Epidemiol Rev. 2004;26:7-21 [15234944.001]
  • [Cites] J Gerontol A Biol Sci Med Sci. 2004 Sep;59(9):M962-5 [15472162.001]
  • [Cites] Milbank Mem Fund Q Health Soc. 1976 Fall;54(4):439-67 [137366.001]
  • [Cites] Soc Sci Med. 1984;19(2):77-91 [6474235.001]
  • [Cites] J Health Soc Behav. 1985 Sep;26(3):156-82 [3905939.001]
  • [Cites] Am J Public Health. 1987 Mar;77(3):307-12 [3812836.001]
  • [Cites] Am J Public Health. 1989 Jun;79(6):703-8 [2729467.001]
  • [Cites] J Am Geriatr Soc. 1990 Sep;38(9):993-8 [2212454.001]
  • [Cites] Soc Sci Med. 1993 Jan;36(1):33-46 [8424182.001]
  • [Cites] Soc Sci Med. 1993 Oct;37(7):905-16 [8211309.001]
  • [Cites] Ann Epidemiol. 1992 Nov;2(6):823-34 [1342335.001]
  • [Cites] Am J Epidemiol. 1996 Apr 15;143(8):766-78 [8610686.001]
  • [Cites] J Aging Health. 1996 Aug;8(3):359-88 [10165980.001]
  • [Cites] BMJ. 1996 Nov 9;313(7066):1177-80 [8916748.001]
  • [Cites] J Gerontol A Biol Sci Med Sci. 1997 Jan;52(1):M19-26 [9008665.001]
  • [Cites] BMJ. 1997 Feb 22;314(7080):547-52 [9055712.001]
  • [Cites] Soc Sci Med. 1997 Nov;45(10):1519-25 [9351141.001]
  • [Cites] Lancet. 1997 Nov 29;350(9091):1584-9 [9393337.001]
  • [Cites] N Engl J Med. 1997 Dec 25;337(26):1889-95 [9407157.001]
  • [Cites] Am J Epidemiol. 1998 Apr 1;147(7):704-8 [9554610.001]
  • [Cites] BMJ. 1998 May 30;316(7145):1631-5 [9603744.001]
  • [Cites] Soc Sci Med. 1999 Jan;48(1):49-60 [10048837.001]
  • [Cites] Soc Sci Med. 1999 Jan;48(1):89-98 [10048840.001]
  • [Cites] Am J Epidemiol. 1999 Apr 1;149(7):654-64 [10192313.001]
  • [Cites] J Health Soc Behav. 1999 Mar;40(1):17-31 [10331319.001]
  • [Cites] Annu Rev Public Health. 1999;20:89-108 [10352851.001]
  • [Cites] Med Care. 2005 Jan;43(1):93-7 [15626939.001]
  • [Cites] J Am Geriatr Soc. 2005 Sep;53(9 Suppl):S317-9 [16131362.001]
  • [Cites] Am J Epidemiol. 2000 Dec 1;152(11):1039-47 [11117613.001]
  • (PMID = 17630374.001).
  • [ISSN] 0143-005X
  • [Journal-full-title] Journal of epidemiology and community health
  • [ISO-abbreviation] J Epidemiol Community Health
  • [Language] eng
  • [Grant] United States / NICHD NIH HHS / HD / R24 HD047861; United States / NICHD NIH HHS / HD / R24 HD047861-01
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2653004
  •  go-up   go-down


44. Aricò M, Conter V, Valsecchi MG, Rizzari C, Boccalatte MF, Barisone E, Messina C, De Rossi G, Lo Nigro L, Pession A, Locatelli F, Micalizzi C, Basso G: Treatment reduction in highly selected standard-risk childhood acute lymphoblastic leukemia. The AIEOP ALL-9501 study. Haematologica; 2005 Sep;90(9):1186-91
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment reduction in highly selected standard-risk childhood acute lymphoblastic leukemia. The AIEOP ALL-9501 study.
  • BACKGROUND AND OBJECTIVES: Treatment of childhood standard-risk (SR) acute lymphoblastic leukemia (ALL) is generally successful.
  • DESIGN AND METHODS: The population of patients with SR ALL included children aged between 1 and 6 years with less than 20,000 WBC/mm3, non-T immunophenotype, DNA index between 1.16 and 1.6, absence of t(9;22) and t(4;11) clonal translocations, no extramedullary leukemia, good response to prednisone and complete remission (CR) at the end of induction therapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / epidemiology

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia, Childhood.
  • Hazardous Substances Data Bank. DAUNORUBICIN .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16154841.001).
  • [ISSN] 1592-8721
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; EC 3.5.1.1 / Asparaginase; VB0R961HZT / Prednisone; ZS7284E0ZP / Daunorubicin; PVDA protocol
  •  go-up   go-down


45. Guastadisegni MC, Lonoce A, Impera L, Albano F, D'Addabbo P, Caruso S, Vasta I, Panagopoulos I, Leszl A, Basso G, Rocchi M, Storlazzi CT: Bone marrow ectopic expression of a non-coding RNA in childhood T-cell acute lymphoblastic leukemia with a novel t(2;11)(q11.2;p15.1) translocation. Mol Cancer; 2008;7:80
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bone marrow ectopic expression of a non-coding RNA in childhood T-cell acute lymphoblastic leukemia with a novel t(2;11)(q11.2;p15.1) translocation.
  • T-cell acute lymphoblastic leukemia (T-ALL) is associated with a large number of such rearrangements.
  • We report the ectopic expression of the 3' portion of EST DA926692 in the bone marrow of a childhood T-ALL case showing a t(2;11)(q11.2;p15.1) translocation as the sole chromosome abnormality.
  • Bioinformatic analysis excluded that this small non-coding RNA is a precursor of micro-RNA, although it is conceivable that it has a different, yet unknown, functional role.
  • To the best of our knowledge, this is the first report, in cancer, of the activation of a small non-coding RNA as a result of a chromosomal translocation.
  • [MeSH-major] Bone Marrow / metabolism. Chromosomes, Human, Pair 11 / genetics. Chromosomes, Human, Pair 2 / genetics. Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / genetics. RNA, Untranslated / genetics. Translocation, Genetic


46. Aricò M, Valsecchi MG, Rizzari C, Barisone E, Biondi A, Casale F, Locatelli F, Lo Nigro L, Luciani M, Messina C, Micalizzi C, Parasole R, Pession A, Santoro N, Testi AM, Silvestri D, Basso G, Masera G, Conter V: Long-term results of the AIEOP-ALL-95 Trial for Childhood Acute Lymphoblastic Leukemia: insight on the prognostic value of DNA index in the framework of Berlin-Frankfurt-Muenster based chemotherapy. J Clin Oncol; 2008 Jan 10;26(2):283-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term results of the AIEOP-ALL-95 Trial for Childhood Acute Lymphoblastic Leukemia: insight on the prognostic value of DNA index in the framework of Berlin-Frankfurt-Muenster based chemotherapy.
  • PURPOSE: Between May 1995 and August 2000 the Associazione Italiana di Ematologia Oncologia Pediatrica conducted the ALL-95 study for risk-directed, Berlin-Frankfurt-Muenster (BFM) -oriented therapy of childhood acute lymphoblastic leukemia, aimed at exploring treatment reduction in standard-risk patients (SR) and intensification during continuation therapy in intermediate-risk patients (IR) as randomized questions and treatment intensification in high-risk patients (HR).
  • SR patients (DNA index >/= 1.16 and < 1.60; age, 1 to 5 years; and WBC < 20,000, non-T-immunophenotype, with no high-risk features) received a reduced induction therapy (no anthracyclines); IR patients were randomly assigned to receive or not receive vincristine and dexamethasone pulses during maintenance; HR therapy was based on a conventional BFM schedule intensified with three chemotherapy blocks followed by a double reinduction phase.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia, Childhood.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. DAUNORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. MERCAPTOPURINE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18182669.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Neoplasm; 04079A1RDZ / Cytarabine; 5J49Q6B70F / Vincristine; 8N3DW7272P / Cyclophosphamide; E7WED276I5 / 6-Mercaptopurine; EC 3.5.1.1 / Asparaginase; VB0R961HZT / Prednisone; YL5FZ2Y5U1 / Methotrexate; ZS7284E0ZP / Daunorubicin; AIEOP acute lymphoblastic leukemia protocol
  •  go-up   go-down


47. Attarbaschi A, Mann G, König M, Steiner M, Strehl S, Schreiberhuber A, Schneider B, Meyer C, Marschalek R, Borkhardt A, Pickl WF, Lion T, Gadner H, Haas OA, Dworzak MN: Mixed lineage leukemia-rearranged childhood pro-B and CD10-negative pre-B acute lymphoblastic leukemia constitute a distinct clinical entity. Clin Cancer Res; 2006 May 15;12(10):2988-94
Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia, Childhood.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mixed lineage leukemia-rearranged childhood pro-B and CD10-negative pre-B acute lymphoblastic leukemia constitute a distinct clinical entity.
  • PURPOSE: Mixed lineage leukemia (MLL) abnormalities occur in approximately 50% of childhood pro-B acute lymphoblastic leukemia (ALL).
  • However, the incidence and type of MLL rearrangements have not been determined in common ALL (cALL) and CD10+ or CD10- pre-B ALL.
  • EXPERIMENTAL DESIGN: To address this question, we analyzed 29 patients with pro-B ALL, 11 patients with CD10- pre-B ALL, 23 pre-B, and 26 cALL patients with CD10 on 20% to 80%, as well as 136 pre-B and 143 cALL patients with CD10 > or = 80% of blasts.
  • RESULTS: We found that 15 of 29 pro-B ALL, 7 of 11 CD10- pre-B ALL, and 1 of 2 French-American-British classification L1 mature B-cell leukemia cases had a MLL rearrangement.
  • MLL-rearranged pro-B and CD10- pre-B ALL cases had similar clinical and immunophenotypic (coexpression of CDw65 and CD15) features at initial diagnosis.
  • CONCLUSIONS: The striking similarities between the two CD10- ALL subsets imply that CD10- pre-B ALL variants may represent pro-B ALL cases that maintained the propensity to rearrange and express their immunoglobulin heavy chain rather than actual pre-B ALL forms transformed at this later stage of B-cell differentiation.
  • [MeSH-major] Chromosome Aberrations. Myeloid-Lymphoid Leukemia Protein / genetics. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16707593.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Immunoglobulin Heavy Chains; 149025-06-9 / Myeloid-Lymphoid Leukemia Protein; EC 3.4.24.11 / Neprilysin
  •  go-up   go-down


48. Fujita N, Mori T, Mitsui T, Inada H, Horibe K, Tsurusawa M, Lymphoma Committee of the Japanese Pediatric Leukemia/Lymphoma Study Group: The role of hematopoietic stem cell transplantation with relapsed or primary refractory childhood B-cell non-Hodgkin lymphoma and mature B-cell leukemia: a retrospective analysis of enrolled cases in Japan. Pediatr Blood Cancer; 2008 Aug;51(2):188-92
Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The role of hematopoietic stem cell transplantation with relapsed or primary refractory childhood B-cell non-Hodgkin lymphoma and mature B-cell leukemia: a retrospective analysis of enrolled cases in Japan.
  • BACKGROUND: There have been excellent treatment results for children with B-cell non-Hodgkin lymphoma (B-NHL) and mature B-cell leukemia (B-ALL) in the last few decades.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation. Leukemia, B-Cell / therapy. Lymphoma, B-Cell / therapy


49. Lalvani A, Millington KA: T cell-based diagnosis of childhood tuberculosis infection. Curr Opin Infect Dis; 2007 Jun;20(3):264-71
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] T cell-based diagnosis of childhood tuberculosis infection.
  • SUMMARY: Although longitudinal studies quantifying risk of progression to tuberculosis in tuberculosis-exposed children with positive TIGRA results are required urgently, the small but rapidly expanding evidence-base since the first application of TIGRAs to childhood tuberculosis in 2003 combined with recent national guidelines makes a strong case for judicious use of TIGRAs in clinical management of paediatric tuberculosis.

  • Genetic Alliance. consumer health - Tuberculosis.
  • MedlinePlus Health Information. consumer health - Tuberculosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17471036.001).
  • [ISSN] 0951-7375
  • [Journal-full-title] Current opinion in infectious diseases
  • [ISO-abbreviation] Curr. Opin. Infect. Dis.
  • [Language] eng
  • [Grant] United Kingdom / Wellcome Trust / /
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 82115-62-6 / Interferon-gamma
  • [Number-of-references] 52
  •  go-up   go-down


50. Raimondi SC, Zhou Y, Shurtleff SA, Rubnitz JE, Pui CH, Behm FG: Near-triploidy and near-tetraploidy in childhood acute lymphoblastic leukemia: association with B-lineage blast cells carrying the ETV6-RUNX1 fusion, T-lineage immunophenotype, and favorable outcome. Cancer Genet Cytogenet; 2006 Aug;169(1):50-7
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Near-triploidy and near-tetraploidy in childhood acute lymphoblastic leukemia: association with B-lineage blast cells carrying the ETV6-RUNX1 fusion, T-lineage immunophenotype, and favorable outcome.
  • The prognostic significance of near-triploidy (68-80 chromosomes) and near-tetraploidy (>80 chromosomes) in childhood acute lymphoblastic leukemia (ALL) is unclear.
  • [MeSH-major] B-Lymphocytes / immunology. Core Binding Factor Alpha 2 Subunit / genetics. Oncogene Proteins, Fusion / genetics. Polyploidy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. T-Lymphocytes / immunology


51. Eidlitz-Markus T, Mukamel M, Haimi-Cohen Y, Amir J, Zeharia A: Breast asymmetry during adolescence: physiologic and non-physiologic causes. Isr Med Assoc J; 2010 Apr;12(4):203-6
MedlinePlus Health Information. consumer health - Breast Diseases.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Breast asymmetry during adolescence: physiologic and non-physiologic causes.
  • BACKGROUND: Pathologic breast conditions are rare in childhood and adolescence.
  • The spectrum of breast disease in the pediatric age group is different from that in adults, and most lesions are benign.
  • METHODS: The files of patients with a diagnosis of breast asymmetry referred to a tertiary pediatric center from 1990 to 2007 were reviewed for history and findings on physical examination with or without imaging, treatment and outcome.
  • In most cases a precise medical history and physical examination can differentiate between physiologic and non-physiologic causes.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20803877.001).
  • [ISSN] 1565-1088
  • [Journal-full-title] The Israel Medical Association journal : IMAJ
  • [ISO-abbreviation] Isr. Med. Assoc. J.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Israel
  •  go-up   go-down


52. Tsurusawa M, Taga T, Horikoshi Y, Ogawa A, Kikuta A, Kanegane H, Matsushita T, Hyakuna N, Shimomura Y, Ohshima K, Lymphoma Committee of Japanese Childhood Cancer and Leukemia: Favourable outcomes in children with diffuse large B-cell lymphoma treated by a short-term ALL-like regimen: a report on the NHL960 study from the Japanese Childhood Cancer and Leukemia Study Group. Leuk Lymphoma; 2008 Apr;49(4):734-9
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Favourable outcomes in children with diffuse large B-cell lymphoma treated by a short-term ALL-like regimen: a report on the NHL960 study from the Japanese Childhood Cancer and Leukemia Study Group.
  • In the NHL960 non-LB study, we treated diffuse large B-cell lymphoma (DLBCL) using a short-term ALL-like protocol.

  • Genetic Alliance. consumer health - Childhood Cancer.
  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18398741.001).
  • [ISSN] 1029-2403
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; 9PHQ9Y1OLM / Prednisolone; D58G680W0G / pirarubicin; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


53. Cario G, Zimmermann M, Romey R, Gesk S, Vater I, Harbott J, Schrauder A, Moericke A, Izraeli S, Akasaka T, Dyer MJ, Siebert R, Schrappe M, Stanulla M: Presence of the P2RY8-CRLF2 rearrangement is associated with a poor prognosis in non-high-risk precursor B-cell acute lymphoblastic leukemia in children treated according to the ALL-BFM 2000 protocol. Blood; 2010 Jul 01;115(26):5393-7
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Presence of the P2RY8-CRLF2 rearrangement is associated with a poor prognosis in non-high-risk precursor B-cell acute lymphoblastic leukemia in children treated according to the ALL-BFM 2000 protocol.
  • High-level expression of the cytokine receptor-like factor 2 gene, CRLF2, in precursor B-cell acute lymphoblastic leukemia (pB-ALL) was shown to be caused by a translocation involving the IGH@ locus or a deletion juxtaposing CRLF2 with the P2RY8 promoter.
  • To assess its possible prognostic value, CRLF2 expression was analyzed in 555 childhood pB-ALL patients treated according to the Acute Lymphoblastic Leukemia Berlin-Frankfurt-Münster 2000 (ALL-BFM 2000) protocol.
  • This difference was mainly attributable to an extremely high incidence of relapse (71% +/- 19%) in non-high-risk patients with P2RY8-CRLF2 rearrangement.
  • [MeSH-major] Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / diagnosis. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / genetics. Receptors, Cytokine / genetics. Receptors, Purinergic P2 / genetics

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Acute Non Lymphoblastic Leukemia.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20378752.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Grant] United Kingdom / Medical Research Council / / MC/ U132670597
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CRLF2 protein, human; 0 / Receptors, Cytokine; 0 / Receptors, Purinergic P2
  •  go-up   go-down


54. Ahmed N, Heslop HE, Mackall CL: T-cell-based therapies for malignancy and infection in childhood. Pediatr Clin North Am; 2010 Feb;57(1):83-96
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] T-cell-based therapies for malignancy and infection in childhood.
  • Adoptive T-cell transfer has shown definite clinical benefit in the prophylaxis and treatment of viral infections that develop in pediatric patients after allogeneic transplant and in posttransplant lymphoproliferative disease associated with the Epstein-Barr virus.
  • This article describes the recent advances in T-cell-based therapies for malignancy and infection in childhood and strategies to enhance the effector functions of T cells and optimize the cellular product, including gene modification and modulation of the host environment.

  • MedlinePlus Health Information. consumer health - Cancer in Children.
  • MedlinePlus Health Information. consumer health - Immunization.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Inc. All rights reserved.
  • [Cites] Blood. 2001 Mar 1;97(5):1458-66 [11222394.001]
  • [Cites] Immunol Res. 2000;22(2-3):253-61 [11339360.001]
  • [Cites] Cancer Res. 2001 Sep 15;61(18):6868-75 [11559563.001]
  • [Cites] J Immunother. 2001 Jul-Aug;24(4):305-11 [11565832.001]
  • [Cites] Cancer Genet Cytogenet. 2002 Mar;133(2):118-23 [11943337.001]
  • [Cites] Histol Histopathol. 2002 Apr;17(2):669-75 [11962766.001]
  • [Cites] Blood. 2002 Jun 1;99(11):3916-22 [12010789.001]
  • [Cites] Am J Pathol. 2002 Jun;160(6):2181-90 [12057921.001]
  • [Cites] Curr Cancer Drug Targets. 2002 Mar;2(1):45-54 [12188920.001]
  • [Cites] Int J Hematol. 2002 Aug;76(2):127-32 [12215010.001]
  • [Cites] Cytotherapy. 2002;4(4):317-27 [12396831.001]
  • [Cites] Immunol Rev. 2002 Oct;188:22-32 [12445278.001]
  • [Cites] Cytotherapy. 2002;4(5):437-8 [12473216.001]
  • [Cites] Nat Rev Cancer. 2003 Jan;3(1):35-45 [12509765.001]
  • [Cites] Nat Rev Cancer. 2003 Jan;3(1):46-54 [12509766.001]
  • [Cites] Cancer Res. 2003 Oct 15;63(20):6948-55 [14583496.001]
  • [Cites] Lancet. 2003 Oct 25;362(9393):1375-7 [14585640.001]
  • [Cites] Int J Cancer. 2004 Feb 20;108(5):704-11 [14696097.001]
  • [Cites] Clin Cancer Res. 2004 Feb 1;10(3):828-39 [14871958.001]
  • [Cites] Int Arch Allergy Immunol. 2004 Feb;133(2):179-97 [14764946.001]
  • [Cites] J Immunother. 2004 Jul-Aug;27(4):317-27 [15235393.001]
  • [Cites] Clin Cancer Res. 2004 Jul 1;10(13):4307-13 [15240516.001]
  • [Cites] Nat Med. 2004 Sep;10(9):909-15 [15340416.001]
  • [Cites] Proc Natl Acad Sci U S A. 1993 Jan 15;90(2):720-4 [8421711.001]
  • [Cites] Cancer Res. 1993 Jul 15;53(14):3257-61 [7686815.001]
  • [Cites] N Engl J Med. 1995 Jan 19;332(3):143-9 [7800006.001]
  • [Cites] N Engl J Med. 1995 Oct 19;333(16):1038-44 [7675046.001]
  • [Cites] J Immunol. 1996 Jun 15;156(12):4609-16 [8648103.001]
  • [Cites] Blood. 1998 Apr 15;91(8):2925-34 [9531603.001]
  • [Cites] J Clin Invest. 1998 May 15;101(10):2290-6 [9593785.001]
  • [Cites] J Clin Invest. 1998 Jul 15;102(2):455-62 [9664088.001]
  • [Cites] Blood. 1998 Sep 1;92(5):1549-55 [9716582.001]
  • [Cites] Clin Cancer Res. 1997 May;3(5):821-6 [9815755.001]
  • [Cites] Clin Cancer Res. 1999 Feb;5(2):335-41 [10037183.001]
  • [Cites] Immunity. 1999 Jun;10(6):673-9 [10403642.001]
  • [Cites] Blood. 1999 Aug 15;94(4):1201-8 [10438707.001]
  • [Cites] Anticancer Res. 1999 May-Jun;19(3B):2205-9 [10472332.001]
  • [Cites] Exp Hematol. 1999 Oct;27(10):1477-86 [10517488.001]
  • [Cites] J Exp Med. 2004 Dec 20;200(12):1623-33 [15611290.001]
  • [Cites] Semin Immunol. 2005 Jun;17(3):183-91 [15826823.001]
  • [Cites] J Clin Invest. 2005 Apr;115(4):930-9 [15776111.001]
  • [Cites] J Immunol. 2005 Jun 1;174(11):6571-6 [15905493.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Jul 5;102(27):9571-6 [15980149.001]
  • [Cites] J Exp Med. 2005 Aug 1;202(3):379-86 [16061727.001]
  • [Cites] Blood. 2005 Dec 15;106(13):4397-406 [16123217.001]
  • [Cites] Cancer Res. 2006 Feb 1;66(3):1818-23 [16452243.001]
  • [Cites] Blood. 2006 Feb 15;107(4):1325-31 [16269610.001]
  • [Cites] Br J Haematol. 2006 Jul;134(1):64-76 [16803570.001]
  • [Cites] Nat Med. 2006 Oct;12(10):1160-6 [16998485.001]
  • [Cites] Clin Cancer Res. 2007 Jan 15;13(2 Pt 1):636-43 [17255287.001]
  • [Cites] Cancer Res. 2007 Jun 15;67(12):5957-64 [17575166.001]
  • [Cites] Blood. 2007 Aug 15;110(4):1123-31 [17468341.001]
  • [Cites] Curr Opin Hematol. 2007 Nov;14(6):616-24 [17898565.001]
  • [Cites] Blood. 2007 Oct 15;110(8):2838-45 [17609424.001]
  • [Cites] Immunol Res. 2007;38(1-3):237-50 [17917029.001]
  • [Cites] Vaccine. 2007 Sep 27;25 Suppl 2:B97-B109 [17916465.001]
  • [Cites] J Exp Med. 2008 Jul 7;205(7):1701-14 [18573906.001]
  • [Cites] Clin Cancer Res. 2008 Aug 1;14(15):4850-8 [18676758.001]
  • [Cites] Blood. 2008 Sep 15;112(6):2261-71 [18509084.001]
  • [Cites] Nat Med. 2008 Nov;14(11):1264-70 [18978797.001]
  • [Cites] Nat Immunol. 2009 Feb;10(2):149-57 [19136960.001]
  • [Cites] Blood. 2009 Mar 12;113(11):2442-50 [18971421.001]
  • [Cites] Mol Ther. 2009 Sep;17(9):1616-25 [19584818.001]
  • [Cites] Blood. 2009 Oct 29;114(18):3831-40 [19704119.001]
  • [Cites] Blood. 2009 Nov 5;114(19):4283-92 [19700662.001]
  • [Cites] Blood. 2009 Nov 5;114(19):4002-8 [19724053.001]
  • [Cites] Blood. 2010 Feb 4;115(5):925-35 [19880495.001]
  • [Cites] Cancer Res. 2000 Apr 1;60(7):1908-13 [10766179.001]
  • [Cites] Nat Med. 2000 Sep;6(9):1018-23 [10973322.001]
  • [Cites] Cancer Res. 2000 Sep 1;60(17):4752-5 [10987281.001]
  • [Cites] Clin Cancer Res. 2000 Oct;6(10):3916-22 [11051238.001]
  • (PMID = 20307713.001).
  • [ISSN] 1557-8240
  • [Journal-full-title] Pediatric clinics of North America
  • [ISO-abbreviation] Pediatr. Clin. North Am.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P50 CA126752-03; United States / NHLBI NIH HHS / HL / HL081007-05; United States / NCI NIH HHS / CA / CA126752-03; United States / NCRR NIH HHS / RR / U42 RR016578-05S1; United States / NCI NIH HHS / CA / P01 CA094237-07; United States / Intramural NIH HHS / / ; United States / NCI NIH HHS / CA / P50 CA126752; United States / NHLBI NIH HHS / HL / U54 HL081007-05; United States / NCI NIH HHS / CA / P01 CA094237; United States / NCI NIH HHS / CA / P01 CA94237; United States / NCRR NIH HHS / RR / RR016578-05S1; United States / NCI NIH HHS / CA / CA094237-07
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, N.I.H., Intramural; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Vaccines
  • [Number-of-references] 72
  • [Other-IDs] NLM/ NIHMS160872; NLM/ PMC2844874
  •  go-up   go-down


55. Burkhardt B, Zimmermann M, Oschlies I, Niggli F, Mann G, Parwaresch R, Riehm H, Schrappe M, Reiter A, BFM Group: The impact of age and gender on biology, clinical features and treatment outcome of non-Hodgkin lymphoma in childhood and adolescence. Br J Haematol; 2005 Oct;131(1):39-49
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The impact of age and gender on biology, clinical features and treatment outcome of non-Hodgkin lymphoma in childhood and adolescence.
  • We analysed the impact of age and gender on biology and outcome of 2084 patients diagnosed with non-Hodgkin lymphoma (NHL) between October 1986 and December 2002 and treated according to the Berlin-Frankfurt-Münster (BFM) multicentre protocols NHL-BFM-86, -90 and -95.
  • Median age at diagnosis was 8.0 years for 97 precursor B-lymphoblastic lymphoma (pB-LBL) patients, 8.8 years for 335 T-lymphoblastic lymphoma (T-LBL) patients, 8.4 years for 1004 Burkitt's lymphoma/leukaemia (BL/B-AL) patients, 11.4 years for 173 diffuse large B-cell lymphoma (centroblastic subtype) (DLBCL-CB) patients, 13.2 years for 40 primary mediastinal large B-cell lymphoma (PMLBL) patients and 10.8 years for 215 anaplastic large-cell lymphoma (ALCL) patients (P < 0.00001).
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, Non-Hodgkin / drug therapy


56. Fowler A, Stödberg T, Eriksson M, Wickström R: Long-term outcomes of acute encephalitis in childhood. Pediatrics; 2010 Oct;126(4):e828-35
Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term outcomes of acute encephalitis in childhood.
  • OBJECTIVES: The aims of this study were to investigate the long-term outcomes of childhood encephalitis and to examine possible prognostic factors.
  • METHODS: Of 93 children who were treated for acute encephalitis in 2000-2004, 71 were eligible for follow-up evaluations.
  • CONCLUSION: Persisting symptoms after childhood encephalitis were present for a substantial number of children.
  • Children who made a full recovery did so within 6 to 12 months, which suggests that all children with encephalitis should be monitored for 1 year after the acute illness.
  • [MeSH-minor] Acute Disease. Adolescent. Child. Child, Preschool. Cognition Disorders / etiology. Electroencephalography. Epilepsy / etiology. Female. Humans. Infant. Male. Personality. Prognosis. Surveys and Questionnaires

  • MedlinePlus Health Information. consumer health - Encephalitis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20876179.001).
  • [ISSN] 1098-4275
  • [Journal-full-title] Pediatrics
  • [ISO-abbreviation] Pediatrics
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


57. Meier M, den Boer ML, Meijerink JP, Broekhuis MJ, Passier MM, van Wering ER, Janka-Schaub GE, Pieters R: Differential expression of p73 isoforms in relation to drug resistance in childhood T-lineage acute lymphoblastic leukaemia. Leukemia; 2006 Aug;20(8):1377-84
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differential expression of p73 isoforms in relation to drug resistance in childhood T-lineage acute lymphoblastic leukaemia.
  • The T-lineage phenotype of childhood acute lymphoblastic leukaemia (ALL) is associated with an increased relapse-risk and in vitro resistance to drugs as compared to a precursor B phenotype.
  • We demonstrate in our study that the expression of total p73 mRNA was higher in childhood T-ALL compared to controls (P=0.004).
  • Our results suggest that childhood T-ALL is associated with a high expression of DeltaTA-p73.
  • [MeSH-major] DNA-Binding Proteins / genetics. Leukemia-Lymphoma, Adult T-Cell / genetics. Nuclear Proteins / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16791269.001).
  • [ISSN] 0887-6924
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA-Binding Proteins; 0 / Nuclear Proteins; 0 / Protein Isoforms; 0 / RNA, Messenger; 0 / Tumor Suppressor Proteins; 0 / tumor suppressor protein p73
  •  go-up   go-down


58. Otsubo K, Kanegane H, Eguchi M, Eguchi-Ishimae M, Tamura K, Nomura K, Abe A, Ishii E, Miyawaki T: ETV6-ARNT fusion in a patient with childhood T lymphoblastic leukemia. Cancer Genet Cytogenet; 2010 Oct 1;202(1):22-6

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] ETV6-ARNT fusion in a patient with childhood T lymphoblastic leukemia.
  • Leukemia with t(1;12)(q21;p13) was previously described in a 5-year-old boy with acute myeloblastic leukemia (AML-M2) who exhibited a novel ETV6-aryl hydrocarbon receptor nuclear translocator (ARNT) fusion protein.
  • We herein report the case of a 2-year-old boy with T-cell lymphoblastic leukemia (T-ALL) harboring t(1;12)(q21;p13).
  • To our knowledge, the current report is novel in its report of the ETV6-ARNT fusion in childhood T-ALL.
  • [MeSH-major] ARNTL Transcription Factors / genetics. Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / genetics. Proto-Oncogene Proteins c-ets / genetics. Repressor Proteins / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20804916.001).
  • [ISSN] 1873-4456
  • [Journal-full-title] Cancer genetics and cytogenetics
  • [ISO-abbreviation] Cancer Genet. Cytogenet.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / ARNTL Transcription Factors; 0 / DNA Primers; 0 / ETS translocation variant 6 protein; 0 / Proto-Oncogene Proteins c-ets; 0 / Repressor Proteins
  •  go-up   go-down


59. Croy I, Schellong J, Gerber J, Joraschky P, Iannilli E, Hummel T: Women with a history of childhood maltreatment exhibit more activation in association areas following non-traumatic olfactory stimuli: a fMRI study. PLoS One; 2010;5(2):e9362
SciCrunch. NeuroSynth: Data: Activation Foci .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Women with a history of childhood maltreatment exhibit more activation in association areas following non-traumatic olfactory stimuli: a fMRI study.
  • BACKGROUND: The aim of this study was investigating how women with a history of childhood maltreatment (CM) process non-threatening and non-trauma related olfactory stimuli.
  • This complements other studies on CM insofar as we found the observed pattern of enhanced activation in associative and emotional regions even following non-traumatic olfactory cues.

  • MedlinePlus Health Information. consumer health - Child Abuse.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Cogn Neurosci. 2000 Jan;12(1):1-47 [10769304.001]
  • [Cites] Int J Psychophysiol. 2000 May;36(2):165-81 [10742571.001]
  • [Cites] J Trauma Stress. 2001 Oct;14(4):843-57 [11776429.001]
  • [Cites] Biol Psychiatry. 2003 Feb 1;53(3):204-10 [12559652.001]
  • [Cites] Conscious Cogn. 2003 Mar;12(1):83-139 [12617864.001]
  • [Cites] Neuroimage. 2003 Mar;18(3):789-97 [12667855.001]
  • [Cites] Neurosci Biobehav Rev. 2003 Jan-Mar;27(1-2):103-17 [12732227.001]
  • [Cites] Neuroimage. 2003 Jul;19(3):1233-9 [12880848.001]
  • [Cites] Stress. 2003 Sep;6(3):151-6 [13129808.001]
  • [Cites] Am J Psychiatry. 2004 Jan;161(1):36-44 [14702248.001]
  • [Cites] Arch Gen Psychiatry. 2004 Feb;61(2):168-76 [14757593.001]
  • [Cites] J Neurophysiol. 2004 Aug;92(2):1153-64 [15056683.001]
  • [Cites] Psychosom Med. 1979 May;41(3):209-18 [472086.001]
  • [Cites] Brain. 1991 Feb;114 ( Pt 1A):71-84 [1998891.001]
  • [Cites] Brain. 1995 Feb;118 ( Pt 1):279-306 [7895011.001]
  • [Cites] J Consult Clin Psychol. 1996 Feb;64(1):22-31 [8907081.001]
  • [Cites] Arch Neurol. 1997 Feb;54(2):162-8 [9041857.001]
  • [Cites] Chem Senses. 1997 Feb;22(1):39-52 [9056084.001]
  • [Cites] Brain. 1998 Jun;121 ( Pt 6):1013-52 [9648540.001]
  • [Cites] Am J Psychiatry. 1999 Apr;156(4):575-84 [10200737.001]
  • [Cites] Biol Psychiatry. 1999 May 15;45(10):1271-84 [10349033.001]
  • [Cites] J Psychiatr Res. 1999 May-Jun;33(3):259-64 [10367992.001]
  • [Cites] Trends Neurosci. 1999 Jul;22(7):310-6 [10370255.001]
  • [Cites] Neuropsychopharmacology. 1999 Jul;21(1):40-50 [10379518.001]
  • [Cites] Physiol Rev. 2005 Jan;85(1):281-317 [15618482.001]
  • [Cites] Trends Cogn Sci. 2005 May;9(5):242-9 [15866151.001]
  • [Cites] J Affect Disord. 2006 Feb;90(2-3):171-4 [16375974.001]
  • [Cites] Am J Psychiatry. 2006 Apr;163(4):630-6 [16585437.001]
  • [Cites] Eur Arch Psychiatry Clin Neurosci. 2006 Apr;256(3):174-86 [16311898.001]
  • [Cites] Adv Otorhinolaryngol. 2006;63:44-69 [16733332.001]
  • [Cites] J Psychiatr Res. 2006 Dec;40(8):709-29 [16214172.001]
  • [Cites] Eur Arch Otorhinolaryngol. 2007 Mar;264(3):237-43 [17021776.001]
  • [Cites] Psychopharmacol Bull. 2007;40(1):8-30 [17285093.001]
  • [Cites] Acta Psychiatr Scand. 2008 Oct;118(4):281-90 [18759808.001]
  • [Cites] Am J Psychiatry. 1999 Nov;156(11):1787-95 [10553744.001]
  • [Cites] Gesundheitswesen. 1999 Dec;61 Spec No:S216-22 [10726424.001]
  • [Cites] Am J Psychiatry. 2001 Nov;158(11):1920-2 [11691703.001]
  • (PMID = 20179758.001).
  • [ISSN] 1932-6203
  • [Journal-full-title] PloS one
  • [ISO-abbreviation] PLoS ONE
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Coffee
  • [Other-IDs] NLM/ PMC2825260
  •  go-up   go-down


60. Mandal C, Srinivasan GV, Chowdhury S, Chandra S, Mandal C, Schauer R, Mandal C: High level of sialate-O-acetyltransferase activity in lymphoblasts of childhood acute lymphoblastic leukaemia (ALL): enzyme characterization and correlation with disease status. Glycoconj J; 2009 Jan;26(1):57-73

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High level of sialate-O-acetyltransferase activity in lymphoblasts of childhood acute lymphoblastic leukaemia (ALL): enzyme characterization and correlation with disease status.
  • Previous studies had established an over-expression of 9-O-acetylated sialoglycoproteins (Neu5,9Ac(2)-GPs) on lymphoblasts of childhood acute lymphoblastic leukaemia (ALL).
  • A newly-developed non-radioactive ELISA can quickly detect sialate-O-acetyltransferase, and thus, may become a suitable tool for ALL-monitoring in larger scale.
  • [MeSH-major] Acetyltransferases / metabolism. Bone Marrow / enzymology. Microsomes / enzymology. Neoplasm Proteins / metabolism. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / enzymology. Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / enzymology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Leukemia. 1999 Feb;13(2):309-12 [10025909.001]
  • [Cites] Biol Chem. 2004 Feb;385(2):145-52 [15101557.001]
  • [Cites] Biochim Biophys Acta. 1961 Sep 16;52:349-60 [14477442.001]
  • [Cites] Eur J Biochem. 2004 Jan;271(2):281-90 [14717696.001]
  • [Cites] Int Immunol. 2005 Feb;17(2):177-91 [15629900.001]
  • [Cites] Cancer Res. 1990 Mar 1;50(5):1403-10 [2302705.001]
  • [Cites] Zoology (Jena). 2004;107(1):49-64 [16351927.001]
  • [Cites] Glycoconj J. 2006 Dec;23(9):627-38 [17115281.001]
  • [Cites] J Biol Chem. 1996 Jun 21;271(25):15130-8 [8662976.001]
  • [Cites] Glycoconj J. 2000 Jul-Sep;17(7-9):485-99 [11421344.001]
  • [Cites] Glycoconj J. 2007 Jan;24(1):17-24 [17146715.001]
  • [Cites] Lancet. 2008 Mar 22;371(9617):1030-43 [18358930.001]
  • [Cites] Glycoconj J. 1998 Sep;15(9):895-904 [10052593.001]
  • [Cites] J Biol Chem. 1988 Feb 5;263(4):2079-86 [3339003.001]
  • [Cites] Biochem Z. 1958;329(6):490-507 [13535603.001]
  • [Cites] J Invest Dermatol. 2001 Feb;116(2):254-60 [11180001.001]
  • [Cites] Hoppe Seylers Z Physiol Chem. 1982 Mar;363(3):255-62 [7076126.001]
  • [Cites] J Biol Chem. 1981 Jan 25;256(2):989-93 [7451485.001]
  • [Cites] Carbohydr Res. 1995 Mar 1;268(1):115-25 [7736461.001]
  • [Cites] Br J Haematol. 2005 Jan;128(1):35-41 [15606547.001]
  • [Cites] Br J Haematol. 2000 Sep;110(4):801-12 [11054061.001]
  • [Cites] Glycobiology. 2004 Oct;14(10):859-70 [15190007.001]
  • [Cites] Int J Cancer. 2004 Aug 20;111(2):270-7 [15197782.001]
  • [Cites] Biol Chem. 2007 Mar;388(3):297-306 [17338637.001]
  • [Cites] Glycoconj J. 1999 Jun;16(6):307-17 [10579699.001]
  • [Cites] Methods Enzymol. 1994;230:168-99 [8139495.001]
  • [Cites] J Biochem. 1998 Jul;124(1):111-21 [9644253.001]
  • [Cites] J Biol Chem. 1979 Feb 10;254(3):789-95 [83994.001]
  • [Cites] Chem Rev. 2002 Feb;102(2):439-69 [11841250.001]
  • [Cites] J Exp Med. 2002 Dec 16;196(12):1535-41 [12486096.001]
  • [Cites] Leukemia. 1999 Jan;13(1):119-25 [10049046.001]
  • [Cites] Cancer Res. 1996 Nov 15;56(22):5165-71 [8912852.001]
  • [Cites] J Biol Chem. 1951 Nov;193(1):265-75 [14907713.001]
  • [Cites] J Biol Chem. 1993 May 15;268(14):10197-206 [8486687.001]
  • [Cites] Anal Biochem. 1989 May 15;179(1):162-6 [2757191.001]
  • [Cites] J Biol Chem. 1985 Jun 10;260(11):6600-8 [3997840.001]
  • [Cites] J Biol Chem. 2006 Mar 24;281(12):7825-33 [16434401.001]
  • [Cites] Biochimie. 1998 Jan;80(1):49-57 [9587662.001]
  • [Cites] Eur J Biochem. 1981 Jun;117(1):41-55 [7262089.001]
  • [Cites] Biochem Biophys Res Commun. 2007 Oct 26;362(3):651-7 [17761143.001]
  • (PMID = 18677580.001).
  • [ISSN] 1573-4986
  • [Journal-full-title] Glycoconjugate journal
  • [ISO-abbreviation] Glycoconj. J.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Neoplasm Proteins; 72-89-9 / Acetyl Coenzyme A; EC 2.3.1.- / Acetyltransferases; EC 2.3.1.- / N-acylneuraminate-9(7)-O-acetyltransferase; F469818O25 / Cytidine Monophosphate; GZP2782OP0 / N-Acetylneuraminic Acid
  •  go-up   go-down


61. Salsano ME, Graziano L, Luongo I, Pilla P, Giordano M, Lama G: Atopy in childhood idiopathic nephrotic syndrome. Acta Paediatr; 2007 Apr;96(4):561-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Atopy in childhood idiopathic nephrotic syndrome.
  • AIM: Aim of the study was to evaluate the immunoallergic pattern and their modulating serum cytokines in children with primary manifestation of nephrotic syndrome, in order to analyse the correlation with disease activity and the outcome of childhood NS.
  • Therefore, specific IgE antibodies were not related to disease activity, suggesting that IgE production might be co-incident in childhood NS.

  • MedlinePlus Health Information. consumer health - Allergy.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17326761.001).
  • [ISSN] 0803-5253
  • [Journal-full-title] Acta paediatrica (Oslo, Norway : 1992)
  • [ISO-abbreviation] Acta Paediatr.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Norway
  • [Chemical-registry-number] 0 / Adrenal Cortex Hormones; 0 / Cytokines; 37341-29-0 / Immunoglobulin E; AYI8EX34EU / Creatinine
  •  go-up   go-down


62. Getahun D, Strickland D, Zeiger RS, Fassett MJ, Chen W, Rhoads GG, Jacobsen SJ: Effect of chorioamnionitis on early childhood asthma. Arch Pediatr Adolesc Med; 2010 Feb;164(2):187-92
MedlinePlus Health Information. consumer health - Asthma in Children.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effect of chorioamnionitis on early childhood asthma.
  • OBJECTIVE: To examine the association between chorioamnionitis and childhood asthma based on gestational age at birth and race/ethnicity.
  • CONCLUSION: Findings suggest that chorioamnionitis at preterm gestation is independently associated with increased risk of childhood asthma.

  • Genetic Alliance. consumer health - Asthma.
  • MedlinePlus Health Information. consumer health - Asthma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20124149.001).
  • [ISSN] 1538-3628
  • [Journal-full-title] Archives of pediatrics & adolescent medicine
  • [ISO-abbreviation] Arch Pediatr Adolesc Med
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


63. Podgornik H, Debeljak M, Zontar D, Cernelc P, Prestor VV, Jazbec J: RUNX1 amplification in lineage conversion of childhood B-cell acute lymphoblastic leukemia to acute myelogenous leukemia. Cancer Genet Cytogenet; 2007 Oct 1;178(1):77-81
MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] RUNX1 amplification in lineage conversion of childhood B-cell acute lymphoblastic leukemia to acute myelogenous leukemia.
  • Amplification of RUNX1 (alias AML1) is a recurrent karyotypic abnormality in childhood acute lymphoblastic leukemia (ALL) that is generally associated with a poor outcome.
  • It does not occur with other primary chromosomal abnormalities in acute ALL.
  • AML1 amplification in acute myelogenous leukemia (AML) is a rare secondary event described mainly in therapy-related cases.
  • AML1 amplification was found in a 13-year-old patient with AML M4/M5 leukemia that occurred 5 years after she had been diagnosed with common B-cell ALL.
  • Conventional cytogenetic, fluorescent in situ hybridization (FISH), and polymerase chain reaction methods revealed no other chromosomal change expected to occur in a disease that we assumed to be a secondary leukemia.
  • [MeSH-major] Core Binding Factor Alpha 2 Subunit / genetics. Gene Expression Regulation, Neoplastic. Leukemia, B-Cell / genetics. Leukemia, B-Cell / pathology. Leukemia, Myeloid, Acute / genetics. Leukemia, Myeloid, Acute / pathology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology


64. Cheung ST, Lee KH, Yeung TH, Tse CY, Tam YH, Chan KW, Yeung CK: Minimally invasive approach in the management of childhood intussusception. ANZ J Surg; 2007 Sep;77(9):778-81
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Minimally invasive approach in the management of childhood intussusception.
  • Non-operative reduction using air enema or other hydrostatic reduction methods has been the standard treatment in most cases.
  • However, if the non-operative method is not indicated or fails, open surgery is still necessary.
  • We herein reviewed our experience of using the combined approach, namely, pneumatic reduction and, if failed, laparoscopic reduction in the management of childhood intussusception.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17685958.001).
  • [ISSN] 1445-1433
  • [Journal-full-title] ANZ journal of surgery
  • [ISO-abbreviation] ANZ J Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


65. Schmiegelow K, Heyman M, Kristinsson J, Mogensen UB, Rosthøj S, Vettenranta K, Wesenberg F, Saarinen-Pihkala U, Nordic Society of Paediatric Haematology and Oncology (NOPHO): Oral methotrexate/6-mercaptopurine may be superior to a multidrug LSA2L2 Maintenance therapy for higher risk childhood acute lymphoblastic leukemia: results from the NOPHO ALL-92 study. J Pediatr Hematol Oncol; 2009 Jun;31(6):385-92
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Oral methotrexate/6-mercaptopurine may be superior to a multidrug LSA2L2 Maintenance therapy for higher risk childhood acute lymphoblastic leukemia: results from the NOPHO ALL-92 study.
  • The importance of maintenance therapy for higher risk childhood acute lymphoblastic leukemia (ALL) is uncertain.
  • Between 1992 and 2001 the Nordic Society for Pediatric Haematology/Oncology compared in a nonrandomized study conventional oral methotrexate (MTX)/6-mercaptopurine (6MP) maintenance therapy with a multidrug cyclic LSA2L2 regimen.
  • [MeSH-major] 6-Mercaptopurine / administration & dosage. Antimetabolites, Antineoplastic / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Methotrexate / administration & dosage. Neoplasm Recurrence, Local / prevention & control. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia, Childhood.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DAUNORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. MERCAPTOPURINE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Pediatr Hematol Oncol. 2009 Jun;31(6):383-4 [19648785.001]
  • (PMID = 19648786.001).
  • [ISSN] 1536-3678
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 5J49Q6B70F / Vincristine; 8N3DW7272P / Cyclophosphamide; E7WED276I5 / 6-Mercaptopurine; VB0R961HZT / Prednisone; YL5FZ2Y5U1 / Methotrexate; ZS7284E0ZP / Daunorubicin; LSA2-L2 protocol
  •  go-up   go-down


66. Teofili L, Giona F, Martini M, Cenci T, Guidi F, Torti L, Palumbo G, Amendola A, Foà R, Larocca LM: Markers of myeloproliferative diseases in childhood polycythemia vera and essential thrombocythemia. J Clin Oncol; 2007 Mar 20;25(9):1048-53
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Markers of myeloproliferative diseases in childhood polycythemia vera and essential thrombocythemia.
  • PURPOSE: Polycythemia vera (PV) and essential thrombocythemia (ET) can present in pediatric age as sporadic or familial diseases.
  • To define the biologic profile of childhood PV and ET, we evaluated specific markers in a cohort of pediatric patients affected by PV and ET, including cases with familial occurrence.

  • Genetic Alliance. consumer health - Essential Thrombocythemia.
  • Genetic Alliance. consumer health - Polycythemia vera.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17369568.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / AR protein, human; 0 / Biomarkers; 0 / CD177 protein, human; 0 / GPI-Linked Proteins; 0 / Isoantigens; 0 / Membrane Glycoproteins; 0 / RNA, Messenger; 0 / Receptors, Androgen; 0 / Receptors, Cell Surface; 0 / Receptors, Erythropoietin; 0 / Receptors, Thrombopoietin; 143641-95-6 / MPL protein, human; 9014-42-0 / Thrombopoietin; EC 2.7.10.2 / JAK2 protein, human; EC 2.7.10.2 / Janus Kinase 2
  •  go-up   go-down


67. Savaşan S, Buck S, Ozdemir O, Hamre M, Asselin B, Pullen J, Ravindranath Y: Evaluation of cytotoxicity by flow cytometric drug sensitivity assay in childhood T-cell acute lymphoblastic leukemia. Leuk Lymphoma; 2005 Jun;46(6):833-40
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation of cytotoxicity by flow cytometric drug sensitivity assay in childhood T-cell acute lymphoblastic leukemia.
  • Risk-based treatment strategies have improved outcome in childhood B-precursor acute lymphoblastic leukemia, and in vitro drug sensitivity assessment using methyl-thiazol-tetrazolium (MTT) assay has been shown to be an independent prognostic marker.
  • To date, such strategies in childhood T-cell acute lymphoblastic leukemia (T-ALL) have proved elusive, and in vitro drug sensitivity testing has had limited success in T-ALL due to poor T-cell lymphoblast survival in vitro.
  • We studied 68 cases of childhood T-ALL for cytarabine (Ara-C) and daunorubicin sensitivity by FCDSA and compared the results with those obtained by MTT assay.
  • Comparison of T-ALL sensitivity with acute myeloid leukemia (AML) cases revealed a unique pattern difference.
  • [MeSH-major] Drug Screening Assays, Antitumor. Flow Cytometry / methods. Medical Oncology / methods. Precursor Cell Lymphoblastic Leukemia-Lymphoma / diagnosis. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy
  • [MeSH-minor] Apoptosis. Bone Marrow Cells / cytology. Bone Marrow Cells / metabolism. Child. Daunorubicin / pharmacology. Humans. Immunophenotyping / methods. Inhibitory Concentration 50. Leukemia, T-Cell / diagnosis. Leukemia, T-Cell / drug therapy. Reproducibility of Results. Sensitivity and Specificity. Tetrazolium Salts / pharmacology. Thiazoles / pharmacology

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia, Childhood.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DAUNORUBICIN .
  • Hazardous Substances Data Bank. METHYLTHIAZOLETETRAZOLIUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16019527.001).
  • [ISSN] 1029-2403
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / U10-CA29691
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Tetrazolium Salts; 0 / Thiazoles; 298-93-1 / thiazolyl blue; ZS7284E0ZP / Daunorubicin
  •  go-up   go-down


68. Conter V, Bartram CR, Valsecchi MG, Schrauder A, Panzer-Grümayer R, Möricke A, Aricò M, Zimmermann M, Mann G, De Rossi G, Stanulla M, Locatelli F, Basso G, Niggli F, Barisone E, Henze G, Ludwig WD, Haas OA, Cazzaniga G, Koehler R, Silvestri D, Bradtke J, Parasole R, Beier R, van Dongen JJ, Biondi A, Schrappe M: Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: results in 3184 patients of the AIEOP-BFM ALL 2000 study. Blood; 2010 Apr 22;115(16):3206-14
Zurich Open Access Repository and Archive. Full text from .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: results in 3184 patients of the AIEOP-BFM ALL 2000 study.
  • The Associazione Italiana di Ematologia Oncologia Pediatrica and the Berlin-Frankfurt-Münster Acute Lymphoblastic Leukemia (AIEOP-BFM ALL 2000) study has for the first time introduced standardized quantitative assessment of minimal residual disease (MRD) based on immunoglobulin and T-cell receptor gene rearrangements as polymerase chain reaction targets (PCR-MRD), at 2 time points (TPs), to stratify patients in a large prospective study.
  • MRD response detected by sensitive quantitative PCR at 2 predefined TPs is highly predictive for relapse in childhood pB-ALL.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biomarkers, Tumor / analysis. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics


69. Dohnal AM, Inthal A, Felzmann T, Glatt S, Sommergruber W, Mann G, Gadner H, Panzer-Grümayer ER: Leukemia-associated antigenic isoforms induce a specific immune response in children with T-ALL. Int J Cancer; 2006 Dec 15;119(12):2870-7

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Leukemia-associated antigenic isoforms induce a specific immune response in children with T-ALL.
  • The potential immunogenicity of acute lymphoblastic leukemia of the T cell (T-ALL), a small subgroup of childhood leukemia with increased risk for treatment failure and early relapse, was addressed by serological identification of leukemia-derived antigens by recombinant expression cloning (SEREX).
  • Given that the leukemia-associated antigens detected in this study have an intracellular localization, the generation of immune effector responses most likely requires antigen presentation.
  • [MeSH-major] Antigens, Neoplasm / immunology. Leukemia-Lymphoma, Adult T-Cell / immunology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2006 Wiley-Liss, Inc.
  • (PMID = 17016825.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies; 0 / Antigens, Neoplasm; 0 / DNA, Complementary; 0 / Protein Isoforms; 0 / RNA, Messenger; 82115-62-6 / Interferon-gamma
  •  go-up   go-down


70. White T, Su S, Schmidt M, Kao CY, Sapiro G: The development of gyrification in childhood and adolescence. Brain Cogn; 2010 Feb;72(1):36-45
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The development of gyrification in childhood and adolescence.
  • Little is known about changes in gyrification during childhood and adolescence, although considering the changes in gray matter volume and thickness during this time period, it is conceivable that alterations in the brain surface morphology could also occur during this period of development.
  • We also present recent findings involving alterations in gyrification during childhood and adolescence.

  • MedlinePlus Health Information. consumer health - Child Development.
  • MedlinePlus Health Information. consumer health - Teen Development.
  • MedlinePlus Health Information. consumer health - Toddler Development.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2009 Elsevier Inc. All rights reserved.
  • [Cites] PLoS Comput Biol. 2006 Mar;2(3):e22 [16557292.001]
  • [Cites] J Exp Biol. 2006 Aug;209(Pt 15):2902-10 [16857874.001]
  • [Cites] Biol Psychiatry. 2006 Sep 1;60(5):463-71 [16566898.001]
  • [Cites] J Anat. 2007 Jan;210(1):66-77 [17229284.001]
  • [Cites] J Exp Child Psychol. 2007 Feb;96(2):107-30 [16828110.001]
  • [Cites] Dev Neuropsychol. 2007;31(1):103-28 [17305440.001]
  • [Cites] IEEE Trans Med Imaging. 2007 Apr;26(4):530-40 [17427740.001]
  • [Cites] Neuroimage. 2002 Feb;15(2):329-44 [11798269.001]
  • [Cites] Dev Med Child Neurol. 2002 Jan;44(1):4-16 [11811649.001]
  • [Cites] Biol Psychiatry. 2002 Feb 1;51(3):208-15 [11839363.001]
  • [Cites] Cereb Cortex. 2002 May;12(5):486-93 [11950766.001]
  • [Cites] Neuron. 2002 Apr 25;34(3):341-7 [11988166.001]
  • [Cites] Science. 2002 Jul 19;297(5580):365-9 [12130776.001]
  • [Cites] Nat Neurosci. 2003 Mar;6(3):309-15 [12548289.001]
  • [Cites] Cereb Cortex. 2003 Jun;13(6):607-11 [12764035.001]
  • [Cites] Biol Psychiatry. 2003 Aug 15;54(4):418-26 [12915286.001]
  • [Cites] J Pediatr. 2003 Oct;143(4 Suppl):S35-45 [14597912.001]
  • [Cites] Science. 2004 Mar 26;303(5666):2033-6 [15044805.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 May 25;101(21):8174-9 [15148381.001]
  • [Cites] Trends Neurosci. 2004 Jul;27(7):392-9 [15219738.001]
  • [Cites] Ann N Y Acad Sci. 2004 Jun;1021:77-85 [15251877.001]
  • [Cites] Nat Neurosci. 2004 Aug;7(8):799-800 [15338563.001]
  • [Cites] J Neurosci. 2004 Sep 22;24(38):8223-31 [15385605.001]
  • [Cites] Neuroimage. 2004;23 Suppl 1:S129-38 [15501082.001]
  • [Cites] Science. 1974 Feb 1;183(4123):425-7 [4203022.001]
  • [Cites] Brain Res. 1973 Nov 9;62(1):1-35 [4203033.001]
  • [Cites] Acta Neuropathol. 1975;31(1):1-12 [1121923.001]
  • [Cites] IEEE Trans Med Imaging. 2008 Feb;27(2):161-70 [18334438.001]
  • [Cites] Brain. 2008 Aug;131(Pt 8):2028-41 [18587151.001]
  • [Cites] Cereb Cortex. 2008 Oct;18(10):2352-7 [18267953.001]
  • [Cites] Cereb Cortex. 2009 Jan;19(1):115-26 [18483006.001]
  • [Cites] Cereb Cortex. 1999 Oct-Nov;9(7):754-63 [10554998.001]
  • [Cites] Am J Psychiatry. 2000 Feb;157(2):275-7 [10671401.001]
  • [Cites] Psychiatry Res. 2000 Feb 28;98(1):1-13 [10708922.001]
  • [Cites] Novartis Found Symp. 2000;228:30-42; discussion 42-52 [10929315.001]
  • [Cites] Neuroimage. 2001 Apr;13(4):577-88 [11305887.001]
  • [Cites] Psychiatry Res. 2001 Jul 1;107(1):29-43 [11472862.001]
  • [Cites] Nat Neurosci. 2001 Dec;4(12):1253-8 [11694885.001]
  • [Cites] Science. 1975 Jul 4;189(4196):18-21 [1135626.001]
  • [Cites] Ann Neurol. 1977 Jan;1(1):86-93 [560818.001]
  • [Cites] Brain Res. 1979 Mar 16;163(2):195-205 [427544.001]
  • [Cites] Prog Brain Res. 1980;53:1-19 [7005941.001]
  • [Cites] J Theor Biol. 1982 Aug 7;97(3):529-38 [6813602.001]
  • [Cites] Brain Behav Evol. 1984;24(2-3):152-67 [6466964.001]
  • [Cites] Science. 1984 Sep 21;225(4668):1258-65 [6474175.001]
  • [Cites] Hum Neurobiol. 1987;6(1):1-9 [3583840.001]
  • [Cites] Science. 1988 Jul 8;241(4862):170-6 [3291116.001]
  • [Cites] Prog Neurobiol. 1989;32(2):137-58 [2645619.001]
  • [Cites] Anat Embryol (Berl). 1988;179(2):173-9 [3232854.001]
  • [Cites] Int J Neurol. 1982-1983;16-17:144-54 [6765658.001]
  • [Cites] Brain Behav Evol. 1989;34(3):143-50 [2512000.001]
  • [Cites] Cereb Cortex. 1991 Sep-Oct;1(5):426-32 [1822750.001]
  • [Cites] Biol Cybern. 1993;70(1):89-94 [8312401.001]
  • [Cites] Neuroimaging Clin N Am. 1994 May;4(2):201-40 [8081626.001]
  • [Cites] Cereb Cortex. 1995 Jan-Feb;5(1):56-63 [7719130.001]
  • [Cites] Science. 1995 Jun 16;268(5217):1578-84 [7777856.001]
  • [Cites] Cereb Cortex. 1995 Jul-Aug;5(4):307-22 [7580124.001]
  • [Cites] Trends Neurosci. 1995 Sep;18(9):383-8 [7482803.001]
  • [Cites] Biol Cybern. 1995 Nov;73(6):529-45 [8527499.001]
  • [Cites] J Neurosci. 1996 Jul 1;16(13):4261-74 [8753887.001]
  • [Cites] Nature. 1997 Jan 23;385(6614):313-8 [9002514.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Mar 4;94(5):1612-4 [9050825.001]
  • [Cites] Brain. 1997 Feb;120 ( Pt 2):257-69 [9117373.001]
  • [Cites] Cell Biochem Biophys. 1995;27(3):135-55 [9279454.001]
  • [Cites] J Comp Neurol. 1997 Oct 20;387(2):167-78 [9336221.001]
  • [Cites] Cereb Cortex. 1998 Jun;8(4):295-300 [9651126.001]
  • [Cites] IEEE Trans Med Imaging. 1998 Dec;17(6):1040-8 [10048861.001]
  • [Cites] Cereb Cortex. 1999 Mar;9(2):151-60 [10220227.001]
  • [Cites] Cereb Cortex. 1999 Sep;9(6):621-6 [10498280.001]
  • [Cites] Trends Cogn Sci. 2004 Sep;8(9):418-25 [15350243.001]
  • [Cites] J Neurosci. 2005 Apr 20;25(16):4146-58 [15843618.001]
  • [Cites] Anat Embryol (Berl). 2005 Dec;210(5-6):411-7 [16175385.001]
  • [Cites] Neuropsychologia. 2006;44(3):445-53 [15985272.001]
  • [Cites] PLoS Comput Biol. 2005 Dec;1(7):e78 [16389299.001]
  • [Cites] Neuroimage. 2006 Feb 15;29(4):1224-30 [16223589.001]
  • (PMID = 19942335.001).
  • [ISSN] 1090-2147
  • [Journal-full-title] Brain and cognition
  • [ISO-abbreviation] Brain Cogn
  • [Language] ENG
  • [Grant] United States / NIMH NIH HHS / MH / K08 MH068540; United States / NCRR NIH HHS / RR / P41 RR00807; United States / NIMH NIH HHS / MH / K08 MH068540-05; United States / PHS HHS / / CON000000004051-3014; United States / NINDS NIH HHS / NS / P30 NS057091; United States / NCRR NIH HHS / RR / RR000400-360552; None / None / / K08 MH068540-05; United States / NIMH NIH HHS / MH / MH068540; United States / NCRR NIH HHS / RR / M01 RR000400-360552
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; Review
  • [Publication-country] United States
  • [Number-of-references] 98
  • [Other-IDs] NLM/ NIHMS162818; NLM/ PMC2815169
  •  go-up   go-down


71. Rimando MG, Chua MN, Yuson Ed, de Castro-Bernas G, Okamoto T: Prevalence of GSTT1, GSTM1 and NQO1 (609C&gt;T) in Filipino children with ALL (acute lymphoblastic leukaemia). Biosci Rep; 2008 Jun;28(3):117-24
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prevalence of GSTT1, GSTM1 and NQO1 (609C>T) in Filipino children with ALL (acute lymphoblastic leukaemia).
  • In the present paper, we examined the incidence of polymorphic genes involved with the detoxification of exogenous chemicals, including carcinogens, namely GSTT1 (glutathione transferase theta1), GSTM1 (glutathione transferase micro1) and NQO1 (NAD(P)H:quinone oxidoreductase 1) in 60 Filipino paediatric patients with ALL (acute lymphoblastic leukaemia).
  • When these two genotypes, GSTM1 null and NQO1 C/C, were combined, the hazard rate for childhood leukaemia was significantly increased (P<0.001).
  • [MeSH-major] Glutathione Transferase / genetics. NAD(P)H Dehydrogenase (Quinone) / genetics. Neoplasm Proteins / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18444911.001).
  • [ISSN] 1573-4935
  • [Journal-full-title] Bioscience reports
  • [ISO-abbreviation] Biosci. Rep.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Neoplasm Proteins; EC 1.6.5.2 / NAD(P)H Dehydrogenase (Quinone); EC 1.6.5.2 / NQO1 protein, human; EC 2.5.1.- / glutathione S-transferase T1; EC 2.5.1.18 / Glutathione Transferase; EC 2.5.1.18 / glutathione S-transferase M1
  •  go-up   go-down


72. Roy A, Bradburn M, Moorman AV, Burrett J, Love S, Kinsey SE, Mitchell C, Vora A, Eden T, Lilleyman JS, Hann I, Saha V, Medical Research Council Childhood Leukaemia Working Party: Early response to induction is predictive of survival in childhood Philadelphia chromosome positive acute lymphoblastic leukaemia: results of the Medical Research Council ALL 97 trial. Br J Haematol; 2005 Apr;129(1):35-44
Hazardous Substances Data Bank. PREDNISOLONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Early response to induction is predictive of survival in childhood Philadelphia chromosome positive acute lymphoblastic leukaemia: results of the Medical Research Council ALL 97 trial.
  • We report on the outcome of children with Philadelphia positive acute lymphoblastic leukaemia (Ph+ ALL) treated on the UK Medical Research Council (MRC) trial for childhood ALL, MRC ALL 97, between January 1997 and June 2002.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Philadelphia Chromosome. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy

  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. DAUNORUBICIN .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15801953.001).
  • [ISSN] 0007-1048
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Grant] United Kingdom / Cancer Research UK / / 14840
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 7S5I7G3JQL / Dexamethasone; 9PHQ9Y1OLM / Prednisolone; ZS7284E0ZP / Daunorubicin
  •  go-up   go-down


73. Koumellis P, McConachie NS, Jaspan T: Spinal subdural haematomas in children with non-accidental head injury. Arch Dis Child; 2009 Mar;94(3):216-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Spinal subdural haematomas in children with non-accidental head injury.
  • OBJECTIVE: To examine the incidence of spinal pathology in infants with non-accidental head injury.
  • METHODS: 18 infants with non-accidental head injury were investigated between 2000 and 2007 with dedicated MRI of the brain and spine.
  • After 2005, all suspected cases of non-accidental head injury were routinely investigated with MRI of the whole spine in addition to the brain.
  • CONCLUSION: There is a high incidence of previously unsuspected spinal subdural haematomas associated with intracranial collections in children with non-accidental head injury.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18713794.001).
  • [ISSN] 1468-2044
  • [Journal-full-title] Archives of disease in childhood
  • [ISO-abbreviation] Arch. Dis. Child.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


74. Roman E, Simpson J, Ansell P, Lightfoot T, Smith A: Infectious proxies and childhood leukaemia: findings from the United Kingdom Childhood Cancer Study (UKCCS). Blood Cells Mol Dis; 2009 Mar-Apr;42(2):126-8
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Infectious proxies and childhood leukaemia: findings from the United Kingdom Childhood Cancer Study (UKCCS).
  • The United Kingdom Childhood Cancer Study (UKCCS) was specifically designed to investigate the potential etiological role of infections as one of its objectives and information on a number of markers of infectious exposure from multiple sources was collected (www.ukccs.org).
  • [MeSH-major] Communicable Diseases / complications. Leukemia / etiology


75. Shah A, Stiller CA, Kenward MG, Vincent T, Eden TO, Coleman MP: Childhood leukaemia: long-term excess mortality and the proportion 'cured'. Br J Cancer; 2008 Jul 8;99(1):219-23
MedlinePlus Health Information. consumer health - Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Childhood leukaemia: long-term excess mortality and the proportion 'cured'.
  • Survival from childhood leukaemia has increased, but the proportion of children cured is unknown.
  • Average time to cure increased from 12 years (95% confidence interval (CI): 11-14) to 19 years (95% CI: 14-26) for lymphoid leukaemia (average annual increase of 0.3 years; P<0.001), but remained at about 5 years for acute nonlymphoblastic leukaemia.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 1998 Oct 1;92(7):2334-7 [9746771.001]
  • [Cites] J Natl Cancer Inst. 1996 Mar 6;88(5):270-8 [8614005.001]
  • [Cites] Br J Cancer. 2004 Nov 29;91(11):1905-10 [15534607.001]
  • [Cites] Br J Haematol. 2005 Jul;130(1):67-75 [15982346.001]
  • [Cites] J Clin Oncol. 2005 Nov 1;23(31):7936-41 [16258093.001]
  • [Cites] Leukemia. 2005 Dec;19(12):2130-8 [16304572.001]
  • [Cites] N Engl J Med. 2006 Oct 12;355(15):1572-82 [17035650.001]
  • [Cites] Br J Cancer. 2007 Apr 10;96(7):1147-52 [17342086.001]
  • [Cites] Br J Haematol. 2000 Mar;108(3):531-43 [10759711.001]
  • [Cites] Blood. 2000 May 1;95(9):2770-5 [10779419.001]
  • [Cites] Leukemia. 2000 Dec;14(12):2307-20 [11187922.001]
  • [Cites] J Clin Oncol. 2001 Jul 1;19(13):3163-72 [11432882.001]
  • [Cites] J Clin Oncol. 2001 Jul 1;19(13):3173-81 [11432883.001]
  • [Cites] Blood. 2002 Jun 15;99(12):4257-64 [12036851.001]
  • [Cites] Br J Haematol. 2003 Aug;122(3):345-59 [12877662.001]
  • [Cites] N Engl J Med. 2003 Aug 14;349(7):640-9 [12917300.001]
  • [Cites] Br J Haematol. 2004 Jan;124(1):33-46 [14675406.001]
  • [Cites] Pediatr Blood Cancer. 2004 Jun;42(7):563-73 [15127410.001]
  • [Cites] Lancet. 1986 Feb 22;1(8478):408-11 [2868339.001]
  • [Cites] Arch Dis Child. 1989 Jun;64(6):798-807 [2774614.001]
  • [Cites] J Clin Epidemiol. 1997 Feb;50(2):211-6 [9120515.001]
  • [Cites] Int J Cancer. 1998 Jul 29;77(3):322-9 [9663589.001]
  • [Cites] J Clin Oncol. 1998 Aug;16(8):2848-53 [9704738.001]
  • [Cites] N Engl J Med. 1991 Nov 7;325(19):1330-6 [1922234.001]
  • [Cites] BMJ. 1994 Jul 16;309(6948):162-6 [8044095.001]
  • [Cites] IARC Sci Publ. 1994;(128):1-302 [7698823.001]
  • [Cites] Stat Med. 1999 Feb 28;18(4):441-54 [10070685.001]
  • (PMID = 18594545.001).
  • [ISSN] 1532-1827
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] ENG
  • [Grant] United Kingdom / Department of Health / /
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2453011
  •  go-up   go-down


76. Rahi JS, Cumberland PM, Peckham CS, British Childhood Visual Impairment Interest Group: Improving detection of blindness in childhood: the British Childhood Vision Impairment study. Pediatrics; 2010 Oct;126(4):e895-903
Genetic Alliance. consumer health - Blindness.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Improving detection of blindness in childhood: the British Childhood Vision Impairment study.
  • OBJECTIVES: In industrialized countries, there are established programs of childhood vision screening and surveillance, but little is known about their performance.
  • METHODS: All children who were younger than 16 years and had a new diagnosis of SVI/BL were identified by active surveillance through the British Ophthalmological and Pediatric Surveillance Units.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20855395.001).
  • [ISSN] 1098-4275
  • [Journal-full-title] Pediatrics
  • [ISO-abbreviation] Pediatrics
  • [Language] eng
  • [Grant] United Kingdom / Department of Health / / ; United Kingdom / Medical Research Council / /
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Investigator] Church W; Forrester J; Kindley D; Rennie A; Benjamin L; Mandal A; Enoch B; Fisher F; Bryars J; McGinnity G; Butler L; Edwards M; Hocking M; Nycyk J; Willshaw H; Benson J; Kelly S; Bradbury J; Day D; Vickers S; Markham R; Williams C; Rauf A; Vivian A; Allen L; Beck L; English M; Lane C; Sastry P; Walters R; Ferris J; Price N; Boodhoo M; Armstrong S; Butcher J; O'Connor G; Dalton C; Dean F; Essex C; Robinson R; Thomson A; Smith R; Birks S; Acheson R; Brosnahan D; Logan P; Bedford G; MacEwen C; Young J; Barr A; Cresswell J; Fleck B; Attenburrow A; Quinn A; Powell P; Dudgeon J; Dutton G; O'Regam M; Al-Rubeyi B; Hutchinson C; Vempali V; Duvall-Young J; Clow D; Innes J; Edelsten C; Goble R; Brennan R; Blamires T; Willshaw L; Carmichael D; Doran R; George N; Bohin S; Woodruff G; Neugebauer M; Chandna A; Clark D; Kaye S; Snelling G; Wright M; Acheson J; Aclimandos W; Adams G; Bloom P; Calver D; Davey C; Duthie A; Fielder A; Gilbert C; Kayali N; Khaw P; Laing G; Lawson J; Lessing D; Moore A; Nischal K; Ohri R; Raina J; Rantell K; Russell-Eggitt I; Salt A; Sloper J; Sullivan P; Taylor D; Thompson G; Heath D; Dady I; Levy R; Lloyd I; Clarke M; Astbury N; Steel S; Gregson R; Crofts B; Esakowitz L; Evans N; Black M; Evans A; Clark S; Billington B; North P; Zaidi A; Burke J; Chan J; Kneen L; Gibbens M; Jones R; Gaston H; Hodgkins P; Morris R; Jalili I; Morrice G; Brown R; Bruce S; Tiffin P; Leitch R; Laws D; Burgess P; Tandy A; Twomey J; Pierse M; Cole M; Munyard P; Stockwell A; Jones S; Dillon A; Noonan C; Thorburn R; MacMahon P; Thompson S; Verghese S; Bradbury A; Banerjee D; Watts J; Shun Shin A; Kaushik N; Taylor R; Donaldson M; Cable N; Rantell K
  •  go-up   go-down


77. Dunwell TL, Hesson LB, Pavlova T, Zabarovska V, Kashuba V, Catchpoole D, Chiaramonte R, Brini AT, Griffiths M, Maher ER, Zabarovsky E, Latif F: Epigenetic analysis of childhood acute lymphoblastic leukemia. Epigenetics; 2009 Apr 1;4(3):185-93
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epigenetic analysis of childhood acute lymphoblastic leukemia.
  • We used a chromosome 3 wide NotI microarray for identification of epigenetically inactivated genes in childhood acute lymphoblastic leukemia (ALL).
  • Three novel genes demonstrated frequent methylation in childhood ALL.
  • In our series of childhood ALL BNC1 was frequently methylated in both T (77%) and B-ALL (79%), whilst MSX1 showed T-ALL (25%) specific methylation.
  • The methylation of the above five genes was cancer specific and expression of the genes could be restored in methylated leukemia cell lines treated with 5-aza-2'-deoxycytidine.
  • This is the first report demonstrating frequent epigenetic inactivation of PPP2R3A, FBLN2, THRB, BNC1 and MSX1 in leukemia.
  • [MeSH-major] Chromosomes, Human, Pair 3 / genetics. DNA Methylation. Epigenesis, Genetic. Gene Expression Regulation, Leukemic. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics


78. Covic T, Roufeil L, Dziurawiec S: Community beliefs about childhood obesity: its causes, consequences and potential solutions. J Public Health (Oxf); 2007 Jun;29(2):123-31
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Community beliefs about childhood obesity: its causes, consequences and potential solutions.
  • BACKGROUND: The objective of this study was to explore community beliefs about the causes, consequences and potential solutions of childhood obesity.
  • METHODS: A convenience sample of 434 adults (41.2 +/- 13.3 years; 61% parents) in New South Wales, Australia, was surveyed using a newly developed childhood obesity scale.
  • Parents did not differ from non-parents across the 12 factors nor were there any differences based on the level of education.
  • CONCLUSIONS: The results of this study suggest that this sample was aware of the complex nature of childhood obesity in terms of its causes, consequences and a range of potential solutions, but they endorsed more family rather than community-based interventions.

  • Genetic Alliance. consumer health - Obesity.
  • MedlinePlus Health Information. consumer health - Obesity.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17507422.001).
  • [ISSN] 1741-3842
  • [Journal-full-title] Journal of public health (Oxford, England)
  • [ISO-abbreviation] J Public Health (Oxf)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


79. Lapinleimu J, Lapinleimu H, Nuotio IO, Rönnemaa T, Simell OG, Viikari JS, STRIP study group: Expression of common familial dyslipidemias in early childhood. Atherosclerosis; 2009 Jun;204(2):573-9
MedlinePlus Health Information. consumer health - Cholesterol.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of common familial dyslipidemias in early childhood.
  • This study estimated the diagnostic values of few early childhood repeatedly deviant lipid samples by the knowledge of the parent's dyslipidemia.
  • Parents' low high-density-lipoprotein-cholesterol concentration (hypo-HDL-C), and high total cholesterol concentration-HDL-C (hyper-non-HDL-C) were defined.
  • True hypo-HDL-C and hyper-non-HDL-C children were defined when their respective individual longitudinal means were beyond the appropriate lipid quintiles.
  • Hyper-non-HDL-C children were 16.7% of all and 31.8% of the children from the hyper-non-HDL-C parents (p=0.008).
  • One early non-HDL-C sample in the highest quintile predicted 56% of the hyper-non-HDL-C children from healthy parents, but 83% of the hyper-non-HDL-C children from the hyper-non-HDL-C parents.
  • This showed that if hypercholesterolemic parent's child expressed repeatedly hyper-non-HDL-C, it predicts true dyslipidemia of the child.

  • MedlinePlus Health Information. consumer health - Atherosclerosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19026413.001).
  • [ISSN] 1879-1484
  • [Journal-full-title] Atherosclerosis
  • [ISO-abbreviation] Atherosclerosis
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Cholesterol, HDL; 0 / Cholesterol, LDL
  •  go-up   go-down


80. Forestier E, Heyman M, Andersen MK, Autio K, Blennow E, Borgström G, Golovleva I, Heim S, Heinonen K, Hovland R, Johannsson JH, Kerndrup G, Nordgren A, Rosenquist R, Swolin B, Johansson B, Nordic Society of Paediatric Haematology, Oncology (NOPHO), Swedish Cytogenetic Leukaemia Study Group (SCLSG), NOPHO Leukaemia Cytogenetic Study Group (NLCSG): Outcome of ETV6/RUNX1-positive childhood acute lymphoblastic leukaemia in the NOPHO-ALL-1992 protocol: frequent late relapses but good overall survival. Br J Haematol; 2008 Mar;140(6):665-72
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcome of ETV6/RUNX1-positive childhood acute lymphoblastic leukaemia in the NOPHO-ALL-1992 protocol: frequent late relapses but good overall survival.
  • The prognostic impact of t(12;21)(p13;q22) [ETV6/RUNX1 fusion] in paediatric acute lymphoblastic leukaemia (ALL) has been extensively debated, particularly with regard to the frequency of late relapses and appropriate treatment regimens.
  • [MeSH-major] Core Binding Factor Alpha 2 Subunit / genetics. Oncogene Proteins, Fusion / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18241254.001).
  • [ISSN] 1365-2141
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Core Binding Factor Alpha 2 Subunit; 0 / Oncogene Proteins, Fusion; 0 / TEL-AML1 fusion protein
  •  go-up   go-down


81. Meleshko AN, Belevtsev MV, Savitskaja TV, Potapnev MP: The incidence of T-cell receptor gene rearrangements in childhood B-lineage acute lymphoblastic leukemia is related to immunophenotype and fusion oncogene expression. Leuk Res; 2006 Jul;30(7):795-800
Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia, Childhood.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The incidence of T-cell receptor gene rearrangements in childhood B-lineage acute lymphoblastic leukemia is related to immunophenotype and fusion oncogene expression.
  • TCR genes rearrangements were reported to occur at high frequency in B-lineage acute lymphoblastic leukemia (ALL).
  • Therefore, we have analyzed 83 children with acute B-lineage ALL (67 de novo patients and 19 relapses) by PCR analysis for clonal IgH, incomplete TCRD (Vdelta2-Ddelta3 and Ddelta2-Ddelta3) and TCRG rearrangements.
  • [MeSH-major] Burkitt Lymphoma / genetics. Core Binding Factor Alpha 2 Subunit / genetics. Fusion Proteins, bcr-abl / genetics. Homeodomain Proteins / genetics. Myeloid-Lymphoid Leukemia Protein / genetics. Oncogene Proteins, Fusion / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. Receptors, Antigen, T-Cell / genetics

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16386788.001).
  • [ISSN] 0145-2126
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Core Binding Factor Alpha 2 Subunit; 0 / Homeodomain Proteins; 0 / MLL-AF4 fusion protein, human; 0 / Oncogene Proteins, Fusion; 0 / Receptors, Antigen, T-Cell; 0 / TEL-AML1 fusion protein; 146150-85-8 / E2A-Pbx1 fusion protein; 149025-06-9 / Myeloid-Lymphoid Leukemia Protein; EC 2.7.10.2 / Fusion Proteins, bcr-abl
  •  go-up   go-down


82. Settin A, Al Haggar M, Al Dosoky T, Al Baz R, Abdelrazik N, Fouda M, Aref S, Al-Tonbary Y: Prognostic cytogenetic markers in childhood acute lymphoblastic leukemia. Indian J Pediatr; 2007 Mar;74(3):255-63
Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia, Childhood.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic cytogenetic markers in childhood acute lymphoblastic leukemia.
  • OBJECTIVE: To evaluate children with acute lymphoblastic leukemia (ALL) showing resistance to immediate induction chemotherapy in relation to conventional and advanced cytogenetic analysis.
  • RESULTS: Cases aged 50.000/mm3 also showed better but non-significant remission rates.
  • CONCLUSION: Some cytogenetic and molecular characterizations of childhood ALL could add prognostic criteria for proper therapy allocation.
  • [MeSH-major] Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Tidsskr Nor Laegeforen. 1998 Jun 20;118(16):2511-8 [9667131.001]
  • [Cites] Cancer Genet Cytogenet. 1997 Dec;99(2):93-6 [9398861.001]
  • [Cites] Clin Genet. 1999 Sep;56(3):192-9 [10563478.001]
  • [Cites] Leukemia. 1994 Nov;8(11):1944-50 [7967740.001]
  • [Cites] Blood. 1992 Jun 15;79(12):3316-24 [1596572.001]
  • [Cites] Br J Haematol. 1982 Nov;52(3):389-99 [6957242.001]
  • [Cites] Cancer Res. 1982 Jul;42(7):2918-29 [6952960.001]
  • [Cites] J Clin Oncol. 1996 Jan;14(1):18-24 [8558195.001]
  • [Cites] Blood. 1999 Mar 15;93(6):2038-42 [10068677.001]
  • [Cites] Ann Hematol. 1999 Apr;78(4):157-62 [10348146.001]
  • [Cites] Br J Haematol. 1981 Jun;48(2):199-206 [6940623.001]
  • [Cites] Blood. 1993 Nov 15;82(10):3163-9 [8219205.001]
  • [Cites] Br J Haematol. 1995 Feb;89(2):364-72 [7873387.001]
  • [Cites] Oncologist. 2000;5(4):321-8 [10965000.001]
  • [Cites] Leuk Res. 2005 Mar;29(3):273-81 [15661262.001]
  • [Cites] Blood. 1993 Nov 15;82(10):3098-102 [8219201.001]
  • [Cites] Med Pediatr Oncol. 1986;14(3):124-34 [3462458.001]
  • [Cites] Blood. 1990 Oct 15;76(8):1449-63 [2207320.001]
  • [Cites] Cancer Genet Cytogenet. 1997 Mar;94(1):8-12 [9078285.001]
  • [Cites] J Clin Pathol. 1986 Sep;39(9):998-1002 [3463568.001]
  • [Cites] Cancer Genet Cytogenet. 1984 Nov;13(3):239-57 [6388821.001]
  • [Cites] Blood. 1992 Feb 15;79(4):871-5 [1737097.001]
  • [Cites] Cancer. 1986 Mar 1;57(5):1046-51 [3484662.001]
  • [Cites] Blood. 1990 Jul 1;76(1):117-22 [2364165.001]
  • [Cites] Pediatr Hematol Oncol. 1993 Jan-Mar;10(1):25-30 [8443048.001]
  • [Cites] Blood. 1996 Apr 1;87(7):2870-7 [8639906.001]
  • [Cites] Br Med J. 1978 Dec 2;2(6151):1529-30 [281981.001]
  • [Cites] Asian Pac J Cancer Prev. 2003 Aug-Dec;4(4):358-68 [14728596.001]
  • [Cites] Br J Haematol. 1999 Apr;105(1):7-24 [10366253.001]
  • [Cites] Blood. 1999 Dec 15;94(12):4036-45 [10590047.001]
  • [Cites] Cancer Genet Cytogenet. 2001 Jul 15;128(2):108-13 [11463448.001]
  • [Cites] Cancer Res. 1981 Nov;41(11 Pt 2):4838-43 [7028252.001]
  • [Cites] Blood. 1996 Oct 1;88(7):2375-84 [8839828.001]
  • [Cites] Br J Haematol. 2004 Jun;125(5):552-9 [15147369.001]
  • [Cites] Singapore Med J. 2003 Oct;44(10):517-20 [15024455.001]
  • [Cites] Lancet. 1981 Apr 4;1(8223):739-43 [6110953.001]
  • [Cites] Rinsho Byori. 1997 Jan;45(1):58-65 [9022344.001]
  • [Cites] Leuk Lymphoma. 1999 May;33(5-6):441-9 [10342572.001]
  • [Cites] N Engl J Med. 1995 Jun 15;332(24):1618-30 [7753142.001]
  • [Cites] Blood. 1986 Jul;68(1):205-12 [3459555.001]
  • [Cites] Blood. 1993 Aug 1;82(3):691-703 [8338938.001]
  • [Cites] Blood. 1993 May 1;81(9):2386-93 [8481519.001]
  • [Cites] J Clin Epidemiol. 2001 Apr;54(4):411-6 [11297891.001]
  • [Cites] Pediatr Clin North Am. 1980 May;27(2):269-91 [6992074.001]
  • [Cites] Science. 1990 Aug 24;249(4971):912-5 [2144057.001]
  • [Cites] Cancer Treat Rep. 1985 Oct;69(10 ):1211-21 [3862465.001]
  • [Cites] J Clin Oncol. 1996 Feb;14(2):389-98 [8636748.001]
  • [Cites] J Clin Oncol. 1997 Jun;15(6):2222-30 [9196134.001]
  • [Cites] Blood. 1989 Nov 1;74(6):2130-5 [2804351.001]
  • [Cites] Clin Lab Med. 2000 Mar;20(1):139-82, x [10702901.001]
  • [Cites] Br J Haematol. 2001 Oct;115(1):34-45 [11722407.001]
  • [Cites] Cancer Genet Cytogenet. 1989 Jul 15;40(2):171-85 [2766242.001]
  • [Cites] Blood. 1999 Jan 1;93(1):315-20 [9864176.001]
  • (PMID = 17401264.001).
  • [ISSN] 0973-7693
  • [Journal-full-title] Indian journal of pediatrics
  • [ISO-abbreviation] Indian J Pediatr
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  •  go-up   go-down


83. Bingham PM, Ashikaga T, Abbasi S: Prospective study of non-nutritive sucking and feeding skills in premature infants. Arch Dis Child Fetal Neonatal Ed; 2010 May;95(3):F194-200
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prospective study of non-nutritive sucking and feeding skills in premature infants.
  • OBJECTIVE: The aim of the present work was to assess the value of non-nutritive sucking (NNS) measures as predictors of oral feeding performance in comparison to other putative predictors of feeding skills: respiratory support, post-menstrual age (PMA) at birth and the neonatal oral motor assessment score (NOMAS).
  • Cox proportional hazards and non-parametric rank sum tests were used to assess the relationship between NNS and feeding outcome measures.

  • MedlinePlus Health Information. consumer health - Infant and Newborn Nutrition.
  • MedlinePlus Health Information. consumer health - Premature Babies.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19948525.001).
  • [ISSN] 1468-2052
  • [Journal-full-title] Archives of disease in childhood. Fetal and neonatal edition
  • [ISO-abbreviation] Arch. Dis. Child. Fetal Neonatal Ed.
  • [Language] eng
  • [Grant] United States / NINR NIH HHS / NR / R01 NR 010166
  • [Publication-type] Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] England
  •  go-up   go-down


84. Hu R, Yan Y, Li Q, Lin Y, Jin W, Li H, Lu Y, Pang T: Increased drug efflux along with midkine gene high expression in childhood B-lineage acute lymphoblastic leukemia cells. Int J Hematol; 2010 Jul;92(1):105-10
Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia, Childhood.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Increased drug efflux along with midkine gene high expression in childhood B-lineage acute lymphoblastic leukemia cells.
  • Multidrug resistance (MDR) induced by drug efflux has been identified as the major clinical obstacle in the treatment of childhood acute lymphoblastic leukemia (ALL).
  • In the Rhodamine 123 (Rh123) efflux test, mean fluorescence intensity (MFI) in the leukemia cells was obviously lower than that in normal pre-B cells (p < 0.01).
  • We concluded that there was powerful drug efflux ability in lymphoblastic leukemia cells with high MK gene expression.
  • [MeSH-major] Drug Resistance, Multiple / genetics. Gene Expression Regulation, Leukemic. Nerve Growth Factors / genetics. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / genetics

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] FEBS Lett. 2006 Feb 13;580(4):998-1009 [16405967.001]
  • [Cites] Neurosci Res. 2003 Feb;45(2):219-24 [12573468.001]
  • [Cites] Oral Oncol. 2004 Mar;40(3):274-80 [14747058.001]
  • [Cites] J Biochem. 2002 Sep;132(3):359-71 [12204104.001]
  • [Cites] Cancer. 2004 Jun 1;100(11):2430-6 [15160348.001]
  • [Cites] Cancer Sci. 2003 Jan;94(1):15-21 [12708468.001]
  • [Cites] Leuk Res. 2007 Aug;31(8):1045-51 [17267033.001]
  • [Cites] Cancer Chemother Pharmacol. 2002 Nov;50(5):343-52 [12439591.001]
  • [Cites] Cancer Res. 2004 Jun 15;64(12):4294-301 [15205344.001]
  • [Cites] Clin Cancer Res. 2004 Jan 1;10(1 Pt 1):272-84 [14734480.001]
  • [Cites] J Biol Chem. 2002 Sep 27;277(39):35990-8 [12122009.001]
  • [Cites] Br J Cancer. 2000 Sep;83(6):701-6 [10952771.001]
  • [Cites] Oncogene. 2005 Jul 21;24(31):4965-74 [15897897.001]
  • [Cites] Nagoya J Med Sci. 2005 Jun;67(3-4):71-82 [17375473.001]
  • [Cites] Exp Hematol. 2008 Apr;36(4):433-42 [18249061.001]
  • [Cites] Cancer Res. 2001 Dec 1;61(23):8486-91 [11731432.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Sep 13;102(37):13266-71 [16141323.001]
  • [Cites] J Biochem. 2000 Feb;127(2):269-77 [10731694.001]
  • (PMID = 20544404.001).
  • [ISSN] 1865-3774
  • [Journal-full-title] International journal of hematology
  • [ISO-abbreviation] Int. J. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / MDK protein, human; 0 / Nerve Growth Factors
  •  go-up   go-down


85. Barman P, Ghosh S, Samajdar S, Mitra U, Dutta P, Bhattacharya SK, Krishnan T, Kobayashi N, Naik TN: RT-PCR based diagnosis revealed importance of human group B rotavirus infection in childhood diarrhoea. J Clin Virol; 2006 Jul;36(3):222-7
MedlinePlus Health Information. consumer health - Rotavirus Infections.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] RT-PCR based diagnosis revealed importance of human group B rotavirus infection in childhood diarrhoea.
  • CONCLUSION: The shift in age preference of group B rotavirus infection from adult to children and mixed infection of group B and group A rotaviruses reveals the importance of group B rotavirus as an etiological agent of childhood diarrhoea.

  • MedlinePlus Health Information. consumer health - Diarrhea.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16765641.001).
  • [ISSN] 1386-6532
  • [Journal-full-title] Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology
  • [ISO-abbreviation] J. Clin. Virol.
  • [Language] eng
  • [Databank-accession-numbers] GENBANK/ AY864913/ AY864914/ AY941776/ AY941777/ AY941778/ AY941779/ AY941789/ AY941790/ AY941791/ AY941792
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  •  go-up   go-down


86. Wang Q, Liu H, Zhang X, Liu Q, Xing Y, Zhou X, Tong C, Zhu P: High doses of mother's lymphocyte infusion to treat EBV-positive T-cell lymphoproliferative disorders in childhood. Blood; 2010 Dec 23;116(26):5941-7

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High doses of mother's lymphocyte infusion to treat EBV-positive T-cell lymphoproliferative disorders in childhood.
  • Among them, 5 children had non-transplant-associated, EBV(+) T-cell LPD.
  • We suggest that high doses of mother's lymphocyte infusion may be an effective and safe treatment for non-transplant-associated EBV(+) T-cell LPD.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20926772.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Viral; 0 / SRY protein, human; 0 / Sex-Determining Region Y Protein
  •  go-up   go-down


87. Baade PD, Youlden DR, Valery PC, Hassall T, Ward L, Green AC, Aitken JF: Trends in incidence of childhood cancer in Australia, 1983-2006. Br J Cancer; 2010 Feb 2;102(3):620-6
MedlinePlus Health Information. consumer health - Cancer in Children.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Trends in incidence of childhood cancer in Australia, 1983-2006.
  • BACKGROUND: There are few population-based childhood cancer registries in the world containing stage and treatment data.
  • METHODS: Data from the population-based Australian Paediatric Cancer Registry were used to calculate incidence rates during the most recent 10-year period (1997-2006) and trends in incidence between 1983 and 2006 for the 12 major diagnostic groups of the International Classification of Childhood Cancer.
  • RESULTS: In the period 1997-2006, there were 6184 childhood cancer (at 0-14 years) cases in Australia (157 cases per million children).
  • For all cancers and for both sexes combined, there was a consistent increase (+0.7% per year, 1983-2006) at age 0-4 years, a slight non-significant increase at 5-9 years, and at 10-14 years, an initial increase (2.7% per year, 1983-1996) followed by a slight non-significant decrease.

  • Genetic Alliance. consumer health - Childhood Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Pediatr Blood Cancer. 2009 Jul;53(1):13-6 [19260104.001]
  • [Cites] Eur J Cancer. 2009 Mar;45(5):747-55 [19117750.001]
  • [Cites] Epidemiology. 2009 Jul;20(4):475-83 [19373093.001]
  • [Cites] JAMA. 2003 Sep 24;290(12):1583-92 [14506117.001]
  • [Cites] J Pediatr Hematol Oncol. 2003 Nov;25(11):854-63 [14608194.001]
  • [Cites] Eur J Cancer. 2004 Jun;40(9):1351-60 [15177495.001]
  • [Cites] Int J Cancer. 1996 Jan 3;65(1):34-8 [8543393.001]
  • [Cites] J Natl Cancer Inst. 1998 Sep 2;90(17):1269-77 [9731733.001]
  • [Cites] Pediatr Blood Cancer. 2004 Dec;43(7):749-57 [15390289.001]
  • [Cites] Lancet. 2004 Dec 11-17;364(9451):2074-6 [15589293.001]
  • [Cites] Lancet. 2004 Dec 11-17;364(9451):2097-105 [15589307.001]
  • [Cites] Cancer. 2005 Apr 1;103(7):1457-67 [15712273.001]
  • [Cites] Lancet. 2005 Jun 18-24;365(9477):2088 [15964441.001]
  • [Cites] Int J Cancer. 2005 Dec 20;117(6):1020-31 [15986434.001]
  • [Cites] Paediatr Drugs. 2006;8(2):71-84 [16608369.001]
  • [Cites] Cancer. 2006 Aug 15;107(4):841-8 [16886175.001]
  • [Cites] Ann N Y Acad Sci. 2006 Sep;1076:29-53 [17119192.001]
  • [Cites] Int J Epidemiol. 2006 Dec;35(6):1495-503 [17008361.001]
  • [Cites] J Natl Cancer Inst. 2007 May 16;99(10):790-800 [17505074.001]
  • [Cites] Arch Dis Child. 2007 Oct;92(10):890-7 [17566053.001]
  • [Cites] Cancer. 2008 Jan 15;112(2):416-32 [18074355.001]
  • [Cites] Pediatr Clin North Am. 2008 Feb;55(1):251-73, xiii [18242324.001]
  • [Cites] Cancer. 2008 Feb 1;112(3):461-72 [18072274.001]
  • [Cites] Int J Cancer. 2008 Apr 15;122(8):1859-67 [18076067.001]
  • [Cites] J Pediatr. 2008 Apr;152(4):458-66 [18346496.001]
  • [Cites] J Pediatr Hematol Oncol. 2008 Feb;30(2):153-9 [18376269.001]
  • [Cites] Int J Cancer. 2008 Jun 1;122(11):2607-11 [18324630.001]
  • [Cites] Pediatrics. 2008 Jun;121(6):e1470-7 [18519450.001]
  • [Cites] West Afr J Med. 2008 Jan;27(1):3-6 [18689295.001]
  • [Cites] J Natl Cancer Inst. 2008 Oct 1;100(19):1368-79 [18812549.001]
  • [Cites] Environ Health Perspect. 2009 Feb;117(2):299-302 [19270803.001]
  • [Cites] Pediatr Blood Cancer. 2009 Jul;53(1):1-2 [19326404.001]
  • (PMID = 20051948.001).
  • [ISSN] 1532-1827
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2822940
  •  go-up   go-down


88. Kusunoki T, Morimoto T, Nishikomori R, Yasumi T, Heike T, Fujii T, Nakahata T: Changing prevalence and severity of childhood allergic diseases in kyoto, Japan, from 1996 to 2006. Allergol Int; 2009 Dec;58(4):543-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Changing prevalence and severity of childhood allergic diseases in kyoto, Japan, from 1996 to 2006.
  • BACKGROUND: Published data regarding changes in the prevalence of childhood allergic diseases in Japan have been limited.
  • METHODS: To observe changes in the recent trends of the childhood allergy epidemic in Japan, a population-based questionnaire survey of allergic diseases was conducted among 13,215 schoolchildren, aged 7 to 15 years, in Kyoto, Japan in 2006.

  • MedlinePlus Health Information. consumer health - Allergy.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19700935.001).
  • [ISSN] 1440-1592
  • [Journal-full-title] Allergology international : official journal of the Japanese Society of Allergology
  • [ISO-abbreviation] Allergol Int
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  •  go-up   go-down


89. Willems M, Haddad E, Niaudet P, Koné-Paut I, Bensman A, Cochat P, Deschênes G, Fakhouri F, Leblanc T, Llanas B, Loirat C, Pillet P, Ranchin B, Salomon R, Ulinski T, Bader-Meunier B, French Pediatric-Onset SLE Study Group: Rituximab therapy for childhood-onset systemic lupus erythematosus. J Pediatr; 2006 May;148(5):623-627
Hazardous Substances Data Bank. RITUXIMAB .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rituximab therapy for childhood-onset systemic lupus erythematosus.
  • OBJECTIVE: To describe the safety and efficacy of rituximab in the treatment of childhood-onset systemic lupus erythematosus (SLE).
  • STUDY DESIGN: We conducted a French multicenter retrospective study of childhood-onset SLE treated with rituximab.

  • Genetic Alliance. consumer health - Lupus.
  • Genetic Alliance. consumer health - Systemic lupus erythematosus.
  • MedlinePlus Health Information. consumer health - Lupus.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Pediatr. 2006 May;148(5):571-3 [16737861.001]
  • [ErratumIn] J Pediatr. 2006 Oct;149(4):586
  • (PMID = 16737873.001).
  • [ISSN] 0022-3476
  • [Journal-full-title] The Journal of pediatrics
  • [ISO-abbreviation] J. Pediatr.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Immunologic Factors; 4F4X42SYQ6 / Rituximab
  •  go-up   go-down


90. Remke M, Pfister S, Kox C, Toedt G, Becker N, Benner A, Werft W, Breit S, Liu S, Engel F, Wittmann A, Zimmermann M, Stanulla M, Schrappe M, Ludwig WD, Bartram CR, Radlwimmer B, Muckenthaler MU, Lichter P, Kulozik AE: High-resolution genomic profiling of childhood T-ALL reveals frequent copy-number alterations affecting the TGF-beta and PI3K-AKT pathways and deletions at 6q15-16.1 as a genomic marker for unfavorable early treatment response. Blood; 2009 Jul 30;114(5):1053-62
SciCrunch. ArrayExpress: Data: Microarray .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High-resolution genomic profiling of childhood T-ALL reveals frequent copy-number alterations affecting the TGF-beta and PI3K-AKT pathways and deletions at 6q15-16.1 as a genomic marker for unfavorable early treatment response.
  • Precursor T-cell acute lymphoblastic leukemia (T-ALL) in children represents a clinical challenge, because relapses are usually fatal.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chromosome Deletion. Chromosomes, Human, Pair 6 / genetics. Neoplasm Proteins / genetics. Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / genetics. Signal Transduction / genetics

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19406988.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Databank-accession-numbers] GEO/ GPL5713/ GSE8738
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CDKN1B protein, human; 0 / Intracellular Signaling Peptides and Proteins; 0 / NOTCH1 protein, human; 0 / Neoplasm Proteins; 0 / Receptor, Notch1; 0 / Transforming Growth Factor beta; 147604-94-2 / Cyclin-Dependent Kinase Inhibitor p27; EC 2.7.1.- / Phosphatidylinositol 3-Kinases; EC 2.7.11.1 / AKT1 protein, human; EC 2.7.11.1 / Proto-Oncogene Proteins c-akt
  •  go-up   go-down


91. Santamaría-Quesada C, Vargas M, Venegas P, Calvo M, Obando C, Valverde B, Cartín W, Carrillo JM, Jimenez R, González M: Molecular and epidemiologic findings of childhood acute leukemia in Costa Rica. J Pediatr Hematol Oncol; 2009 Feb;31(2):131-5
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Molecular and epidemiologic findings of childhood acute leukemia in Costa Rica.
  • In Central America, nearly 70% of pediatric cancer is related to hemato-oncologic disorders, especially acute lymphoblastic leukemia (ALL).
  • Preliminary studies have described a high incidence of childhood leukemia in these countries; however, no molecular analyses of these malignancies have yet been carried out.
  • We studied diagnostic samples from 84 patients from the National Children's Hospital in San Jose, Costa Rica (65 precursor B-ALL, 5 T-cell ALL, and 14 acute myeloblastic leukemia).
  • The observed rate of leukemia was 52.2 cases per million children per year.
  • Within 14 acute myeloblastic leukemia patients, we confirmed 2 cases with FLT3-internal tandem duplication+, 1 patient with AML1-ETO, and only 1 case carrying a PML-RARalpha rearrangement.
  • The present study confirms the relatively high incidence of pediatric leukemia in Costa Rica and constitutes the first report regarding the incidence of the main molecular alterations of childhood leukemia in our region.
  • [MeSH-major] Leukemia / epidemiology. Leukemia / genetics
  • [MeSH-minor] Acute Disease. Child. Costa Rica / epidemiology. Cytogenetic Analysis. Gene Rearrangement. Humans. Mutation. Oncogene Proteins, Fusion / analysis

  • MedlinePlus Health Information. consumer health - Leukemia.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19194200.001).
  • [ISSN] 1536-3678
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Oncogene Proteins, Fusion
  •  go-up   go-down


92. Ozen S, Ruperto N, Dillon MJ, Bagga A, Barron K, Davin JC, Kawasaki T, Lindsley C, Petty RE, Prieur AM, Ravelli A, Woo P: EULAR/PReS endorsed consensus criteria for the classification of childhood vasculitides. Ann Rheum Dis; 2006 Jul;65(7):936-41
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] EULAR/PReS endorsed consensus criteria for the classification of childhood vasculitides.
  • OBJECTIVE: To develop a widely accepted general classification for the vasculitides observed in children and specific and realistic classification criteria for common childhood vasculitides (Henoch-Schönlein purpura (HSP), Kawasaki disease (KD), childhood polyarteritis nodosa (PAN), Wegener's granulomatosis (WG), and Takayasu arteritis (TA)).
  • RESULTS: Consensus was reached to base the general working classification for childhood vasculitides on vessel size.
  • The small vessel disease was further subcategorised into "granulomatous" and "non-granulomatous."
  • Final criteria were developed to classify a child as HSP, KD, childhood PAN, WG, or TA, with changes introduced based on paediatric experience.

  • MedlinePlus Health Information. consumer health - Vasculitis.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Lancet. 1999 Jul 24;354(9175):327-30 [10440326.001]
  • [Cites] J Rheumatol. 1999 Feb;26(2):504-7 [9972996.001]
  • [Cites] Int J Cardiol. 2000 Aug 31;75 Suppl 1:S153-7 [10980355.001]
  • [Cites] Pediatr Nephrol. 2002 Apr;17(4):277-83 [11956882.001]
  • [Cites] Pediatr Nephrol. 2002 Sep;17(9):754-61 [12215830.001]
  • [Cites] Rheumatology (Oxford). 2003 Dec;42(12):1452-9 [12832713.001]
  • [Cites] J Pediatr. 2004 Oct;145(4):517-22 [15480378.001]
  • [Cites] Arerugi. 1967 Mar;16(3):178-222 [6062087.001]
  • [Cites] Pediatrics. 1988 May;81(5):736 [3357740.001]
  • [Cites] Arthritis Rheum. 1990 Aug;33(8):1088-93 [1975174.001]
  • [Cites] Arthritis Rheum. 1990 Aug;33(8):1101-7 [2202308.001]
  • [Cites] Arthritis Rheum. 1990 Aug;33(8):1114-21 [2202310.001]
  • [Cites] Arthritis Rheum. 1990 Aug;33(8):1129-34 [1975175.001]
  • [Cites] J Pediatr. 1992 Feb;120(2 Pt 1):206-9 [1346538.001]
  • [Cites] Arthritis Rheum. 1994 Feb;37(2):181-6 [8129772.001]
  • [Cites] Arthritis Rheum. 1994 Feb;37(2):187-92 [8129773.001]
  • [Cites] Arthritis Rheum. 1995 Jun;38(6):727-35 [7779114.001]
  • [Cites] Arthritis Rheum. 1997 Jul;40(7):1202-9 [9214419.001]
  • [Cites] Pediatrics. 2004 Dec;114(6):1708-33 [15574639.001]
  • (PMID = 16322081.001).
  • [ISSN] 0003-4967
  • [Journal-full-title] Annals of the rheumatic diseases
  • [ISO-abbreviation] Ann. Rheum. Dis.
  • [Language] eng
  • [Publication-type] Consensus Development Conference; Journal Article
  • [Publication-country] England
  • [Number-of-references] 23
  • [Other-IDs] NLM/ PMC1798210
  •  go-up   go-down


93. Wandroo F, Bell A, Darbyshire P, Pratt G, Stankovic T, Gordon J, Lawson S, Moss P: ZAP-70 is highly expressed in most cases of childhood pre-B cell acute lymphoblastic leukemia. Int J Lab Hematol; 2008 Apr;30(2):149-57
Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia, Childhood.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] ZAP-70 is highly expressed in most cases of childhood pre-B cell acute lymphoblastic leukemia.
  • ZAP-70 is, however, expressed in adult B cell chronic lymphocytic leukemia where it correlates with a poor prognosis.
  • We wished to determine if ZAP-70 is also expressed in pediatric B cell malignancy.
  • ZAP-70 expression was then determined in bone marrow lymphoblasts obtained from 12 patients with pre-B cell acute lymphoblastic leukemia (ALL).
  • ZAP-70 expression was strongly expressed in nine of the 12 cases of primary pre-B cell lymphoblastic leukemia.
  • The T cell-associated protein kinase ZAP-70 is highly expressed in pre-B lineage cells and most cases of pre-B acute lymphoblastic leukemia.
  • ZAP-70 expression may hold prognostic value for pre-B ALL and raises the prospect of a novel therapeutic target.
  • [MeSH-major] B-Lymphocytes / metabolism. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / metabolism. Precursor Cells, B-Lymphoid / metabolism. ZAP-70 Protein-Tyrosine Kinase / metabolism

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18333847.001).
  • [ISSN] 1751-5521
  • [Journal-full-title] International journal of laboratory hematology
  • [ISO-abbreviation] Int J Lab Hematol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] EC 2.7.10.2 / ZAP-70 Protein-Tyrosine Kinase; EC 2.7.10.2 / ZAP70 protein, human
  •  go-up   go-down


94. Sun XF, Zhen ZJ, Lui DG, Xia Y, He YJ, Wang ZH, Lin JY, Guan ZZ: Improved treatment outcome in Chinese children and adolescents with Burkitt's lymphoma and large cell lymphoma by using the modified B-non-Hodgkin's lymphoma-Berlin-Frankfurt-Münster-90 protocol. Eur J Haematol; 2006 Nov;77(5):365-71
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Improved treatment outcome in Chinese children and adolescents with Burkitt's lymphoma and large cell lymphoma by using the modified B-non-Hodgkin's lymphoma-Berlin-Frankfurt-Münster-90 protocol.
  • OBJECTIVES: This study was designed to evaluate the efficacy and toxicity of the modified B-Non-Hodgkin's Lymphoma (NHL)-Berlin-Frankfurt-Münster (BFM)-90-based protocol in Chinese children and adolescents with Burkitt's lymphoma and large cell lymphoma.
  • CONCLUSIONS: This modified NHL-BFM-90 protocol is very effective for Chinese children and adolescents with BKL and large cell lymphomas, and represented an increase in the cure rates in childhood NHL in China.

  • Genetic Alliance. consumer health - Lymphoma, large-cell.
  • Genetic Alliance. consumer health - Burkitt's Lymphoma.
  • Hazardous Substances Data Bank. DAUNORUBICIN .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16879606.001).
  • [ISSN] 0902-4441
  • [Journal-full-title] European journal of haematology
  • [ISO-abbreviation] Eur. J. Haematol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; EC 3.5.1.1 / Asparaginase; VB0R961HZT / Prednisone; ZS7284E0ZP / Daunorubicin; PVDA protocol
  •  go-up   go-down


95. Karrman K, Andersson A, Björgvinsdóttir H, Strömbeck B, Lassen C, Olofsson T, Nguyen-Khac F, Berger R, Bernard O, Fioretos T, Johansson B: Deregulation of cyclin D2 by juxtaposition with T-cell receptor alpha/delta locus in t(12;14)(p13;q11)-positive childhood T-cell acute lymphoblastic leukemia. Eur J Haematol; 2006 Jul;77(1):27-34
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Deregulation of cyclin D2 by juxtaposition with T-cell receptor alpha/delta locus in t(12;14)(p13;q11)-positive childhood T-cell acute lymphoblastic leukemia.
  • OBJECTIVES: The t(12;14)(p13;q11)--a recurrent translocation in childhood T-cell acute lymphoblastic leukemia (T-ALL)--has very recently been molecularly characterized in one case, which displayed overexpression of the cyclin D2 gene (CCND2).
  • PATIENTS AND METHODS: We have characterized two pediatric t(12;14)-positive T-ALLs using fluorescence in situ hybridization (FISH), cDNA microarray, and real-time polymerase chain reaction (PCR).
  • The t(12;14)-positive T-ALL displayed an increased expression of CCND2 compared to the controls, whereas the expression of the other genes was similar in all T-ALLs.
  • [MeSH-major] Cyclins / genetics. Gene Expression Regulation, Neoplastic. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. Receptors, Antigen, T-Cell, alpha-beta / genetics. Receptors, Antigen, T-Cell, gamma-delta / genetics. Translocation, Genetic

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia, Childhood.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16548914.001).
  • [ISSN] 0902-4441
  • [Journal-full-title] European journal of haematology
  • [ISO-abbreviation] Eur. J. Haematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / CCND2 protein, human; 0 / Cyclin D2; 0 / Cyclins; 0 / Receptors, Antigen, T-Cell, alpha-beta; 0 / Receptors, Antigen, T-Cell, gamma-delta
  •  go-up   go-down


96. Szatmari P, Bryson S, Duku E, Vaccarella L, Zwaigenbaum L, Bennett T, Boyle MH: Similar developmental trajectories in autism and Asperger syndrome: from early childhood to adolescence. J Child Psychol Psychiatry; 2009 Dec;50(12):1459-67
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Similar developmental trajectories in autism and Asperger syndrome: from early childhood to adolescence.
  • OBJECTIVE: The objective of this study was to chart the developmental trajectories of high-functioning children with autism spectrum disorders (ASD) from early childhood to adolescence using the presence and absence of structural language impairment (StrLI) as a way of differentiating autism from Asperger syndrome (AS).
  • The differences in outcome could not be explained by non-verbal IQ or change in early language skills.

  • Genetic Alliance. consumer health - Asperger Syndrome.
  • Genetic Alliance. consumer health - Autism.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Child Psychol Psychiatry. 2009 Dec;50(12):1439-40 [20059624.001]
  • (PMID = 19686332.001).
  • [ISSN] 1469-7610
  • [Journal-full-title] Journal of child psychology and psychiatry, and allied disciplines
  • [ISO-abbreviation] J Child Psychol Psychiatry
  • [Language] eng
  • [Grant] Canada / Canadian Institutes of Health Research / /
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


97. Fowler A, Stödberg T, Eriksson M, Wickström R: Childhood encephalitis in Sweden: etiology, clinical presentation and outcome. Eur J Paediatr Neurol; 2008 Nov;12(6):484-90
MedlinePlus Health Information. consumer health - Encephalitis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Childhood encephalitis in Sweden: etiology, clinical presentation and outcome.
  • Acute encephalitis is a relatively uncommon but potentially harmful CNS inflammation usually caused by infection.
  • Furthermore, the long-term prognosis of acute encephalitis in children is poorly described.
  • In this study, we characterize childhood encephalitis from a Swedish perspective in regard to etiology, clinical presentation and sequele.
  • We retrospectively studied all children (n=93) who were admitted for acute encephalitis at Karolinska University Hospital in Stockholm during 2000-2004.
  • [MeSH-minor] Acute Disease. Adolescent. Age Factors. Child. Child, Preschool. Clinical Laboratory Techniques. Electroencephalography. Female. Humans. Infant. Inflammation / pathology. Magnetic Resonance Imaging. Male. Sex Factors. Sweden / epidemiology. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18313340.001).
  • [ISSN] 1090-3798
  • [Journal-full-title] European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society
  • [ISO-abbreviation] Eur. J. Paediatr. Neurol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


98. Matricardi PM, Illi S, Grüber C, Keil T, Nickel R, Wahn U, Lau S: Wheezing in childhood: incidence, longitudinal patterns and factors predicting persistence. Eur Respir J; 2008 Sep;32(3):585-92
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Wheezing in childhood: incidence, longitudinal patterns and factors predicting persistence.
  • Childhood asthma is frequently perceived as a disease with uniform clinical pathways.

  • MedlinePlus Health Information. consumer health - Asthma.
  • MedlinePlus Health Information. consumer health - Asthma in Children.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Eur Respir J. 2009 Mar;33(3):700-1 [19251809.001]
  • (PMID = 18480107.001).
  • [ISSN] 1399-3003
  • [Journal-full-title] The European respiratory journal
  • [ISO-abbreviation] Eur. Respir. J.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  •  go-up   go-down


99. Nordly S, Mortensen HB, Andreasen AH, Hermann N, Jørgensen T: Factors associated with glycaemic outcome of childhood diabetes care in Denmark. Diabet Med; 2005 Nov;22(11):1566-73
MedlinePlus Health Information. consumer health - Diabetes in Children and Teens.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Factors associated with glycaemic outcome of childhood diabetes care in Denmark.
  • METHODS: Data for this cross-sectional study originated from the nationwide Danish Registry for Childhood Diabetes and two questionnaires.
  • The structure indicators were not associated with outcome, necessitating more detailed studies on the influence of staffing resources, treatment strategies and targets in childhood diabetes management.

  • Genetic Alliance. consumer health - Diabetes.
  • MedlinePlus Health Information. consumer health - A1C.
  • MedlinePlus Health Information. consumer health - Choosing a Doctor or Health Care Service.
  • MedlinePlus Health Information. consumer health - Diabetes.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16241923.001).
  • [ISSN] 0742-3071
  • [Journal-full-title] Diabetic medicine : a journal of the British Diabetic Association
  • [ISO-abbreviation] Diabet. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Hemoglobin A, Glycosylated
  •  go-up   go-down


100. Kupka RW, Luckenbaugh DA, Post RM, Suppes T, Altshuler LL, Keck PE Jr, Frye MA, Denicoff KD, Grunze H, Leverich GS, McElroy SL, Walden J, Nolen WA: Comparison of rapid-cycling and non-rapid-cycling bipolar disorder based on prospective mood ratings in 539 outpatients. Am J Psychiatry; 2005 Jul;162(7):1273-80
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparison of rapid-cycling and non-rapid-cycling bipolar disorder based on prospective mood ratings in 539 outpatients.
  • OBJECTIVE: To detect risk factors for rapid cycling in bipolar disorder, the authors compared characteristics of rapid-cycling and non-rapid-cycling patients both from a categorical and a dimensional perspective.
  • RESULTS: Patients with rapid cycling (N=206; 38.2%) significantly differed from those without rapid cycling (N=333) with respect to the following independent variables: history of childhood physical and/or sexual abuse, bipolar I disorder subtype, number of lifetime manic or depressive episodes, history of rapid cycling, and history of drug abuse.

  • Genetic Alliance. consumer health - Bipolar Disorder.
  • MedlinePlus Health Information. consumer health - Bipolar Disorder.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15994709.001).
  • [ISSN] 0002-953X
  • [Journal-full-title] The American journal of psychiatry
  • [ISO-abbreviation] Am J Psychiatry
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down






Advertisement